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1. Introduction 
Tuberculosis (TB) is a major global public health problem around the world. It 
remains one of the leading infectious causes of morbidity and mortality. Mycobacterium 
tuberculosis (M. tb) is estimated to have infected one-third of the world’s population (WHO: 
Tuberculosis facts, 2007). Annually, around 9 million people develop an active form of the 
disease with subsequent nearly 2 million deaths worldwide (Geraldes Santos et al., 2007). 
Regionally, the majority of TB cases in 2008 existed in Asia (55%) and Africa (30%), with 
noticeable decrease of cases in the Eastern Mediterranean (7%), Europe (5%), and the 
Americas (3%) (Haydel, 2010).  
 
 
Fig. (1): Estimated TB incidence rates, 2010. Source: (WHO: Global tuberculosis control, 
2011) 
 
TB infects mainly the lung parenchyma (pulmonary TB) however; extra-pulmonary 
TB represents also a common clinical feature in which the bacillus penetrates other organs 
such as lymph nodes, abdomen, pleura, genitourinary tract, skin, joints, bones, meninges, 
pericardium, larynx, breast and female genital tract (Sharma & Mohan, 2004). Fever, loss of 
weight, and a typical cough with blood and sputum are the usual manifestations of the disease.  
Bacille Calmette-Guérin (BCG) vaccine, which is an alive attenuated strain of M. bovis, is the 
only currently used vaccine (Daele & Calenbergh, 2005). The widespread use of the vaccine is 
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controversial as it failed to decrease the pandemic of TB. In addition; recent data suggested 
that BCG might also have accelerated the development of even more virulent forms of TB. 
On the other hand, it could be valuable in preventing the less frequent severe forms in 
children such meningitis and systemic disease (Marriner et al., 2011) (Young & Dye, 2006). 
 
TB is an air born infection which is transmitted as a highly infectious aerosol. The fate 
of the initial exposure to M. tb varies from immediate elimination of the organism by the 
host’s innate immune response to infected individuals developing active primary TB (Flynn & 
Chan, 2001). However, the most of exposed cases develop a latent infection with no clinical 
symptoms. These patients have the risk of 5-10 % to develop the active form during their life 
even with the absence of any cause of immunosuppression (Clark-Curtiss & Haydel, 2003). 
 
Other aspect that contributed markedly to aggravate the situation is the co-infection 
with human immunodeficiency virus (HIV) in which TB and HIV synergistically influence 
the progress of each other’s. HIV positive individuals have a 60-fold greater risk to develop 
active TB (Corbett et al., 2003).  The treatment of the dual infection is more complicated due 
to the negative interaction between antiviral and anti-TB drugs, especially rifampicin (RIF) 
which accelerates the metabolism of several antiviral drugs. Furthermore, the 
immunosuppression with HIV enhances the rate of TB relapse (Aaron et al, 2004). Currently, 
around one-third of HIV positive individuals are co-infected with TB (Haydel, 2010). 
 
1.1    Tuberculosis treatment and drug resistance: 
1.1.1 Recommended treatment and current anti-TB antibiotics: 
As recommended by the world health organization (WHO), the standard treatment 
initiated during the first two months by daily administration of the first-line anti-TB drugs; 
isoniazid (INH), RIF, pyrazinamide (PZA), and ethambutol. In the continuation phase, INH 
and RIF are administered for additional 4 to 12 months. (WHO: treatment of tuberculosis 
guidelines, 2010). This standardized treatment regimen is a part of (DOTS), the Directly 
Observed Treatment Short-course. This strategy was developed to shorten the length of the 
illness, to lower the mortality rate and to avoid the development of drug resistance. It depends 
on five principal elements: political commitment for financing, proper case detection with 
appropriate laboratory techniques, standard chemotherapeutic treatment, a monitoring system 
and a direct observation of the treatment (Daele & Calenbergh, 2005). 
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First-line anti-TB antibiotics (Table-1) work mainly against actively replicating M. tb, 
thus reducing the spread of infection to other individuals during the first two months of 
treatment.  The sterilizing property of RIF during the short-course antibiotic regimen is 
referred to its activity against dormant bacteria (Haydel, 2010). PZA has a powerful activity 
against dormant and slow replicating M. tb under acidic and hypoxic conditions inside 
macrophages and in the pulmonary caseous lesions (Zhang et al., 2003) (Zhang & Mitchison, 
2003). When resistance to INH is suspected, adding ethambutol to the first-line drug regimen 
is recommended to prevent RIF-resistance (American thoracic society and infectious diseases 
society of America, 2003). 
 
Table (1): First line anti-tuberculosis drugs (Haydel, 2010). 
First-line 
drug Antibiotic class Route Activity 
Mechanism of 
action 
Genes and products 
related to resistance 
 Isoniazid Pyridine hydrazide Oral Bactericidal 
Inhibition of cell 
wall synthesis 
(mycolic acid) 
 
1- katG:      
catalaseperoxidase 
 
2- inhA: 
enoyl-ACP Reductase 
 
3- ndh: 
NADH dehydrogenase 
II 
Rifampicin Rifamycin Oral Bactericidal 
Inhibition of  
RNA synthesis 
(RNAP) 
rpoB: 
β-subunit of RNA 
polymerase 
 
Pyrazinamide Nicotinamide analogue Oral 
Bacteriostatic 
/  
bactericidal 
Acidification of 
the cytoplasm & 
disruption of the 
cell wall function 
pncA: 
nicotinamidase/ 
pyrazinamidase 
Ethambutol Ethylenediamine derivative Oral Bacteriostatic 
Inhibition of cell 
wall synthesis 
(arabinogalactan) 
 
embCAB: 
arabinosyl transferase 
 
 
 
The second-line drugs (table-2) are introduced to the drug regimen with the resistance 
to the first-line. Each member of the second-line has its own problems, either lower potency, 
higher toxicity or the expensive cost (Dorman & Chaisson, 2007) (Moore-Gillon, 2001). 
 
 
4 
 
Table (2): Second line anti-tuberculosis drugs (Haydel, 2010). 
second-line 
drug 
Antibiotic 
class Route Activity 
Mechanism 
of action 
Genes and products 
related to resistance 
Streptomycin Aminoglycoside IM Bactericidal 
Inhibition of 
protein 
synthesis 
1- rpsL: 
S12 ribosomal protein 
 
2- rrs: 
16S rRNA 
Kanamycin/ 
Amikacin Aminoglycoside IM Bactericidal 
Inhibition of 
protein 
synthesis 
 
rrs: 16S rRNA 
Capreomycin Polypeptide IM Bactericidal 
Inhibition of 
protein 
synthesis 
1- rrs: 
16S rRNA 
 
2- tlyA: 
Putative rRNA 
methyltransferase 
Levofloxacin Fluoroquinolone Oral or IV Bactericidal 
Inhibition of 
DNA 
replication 
gyrA: 
DNA gyrase subunit A 
Moxifloxacin Fluoroquinolone Oral or IV Bactericidal 
Inhibition of 
DNA 
replication 
gyrA: 
DNA gyrase subunit A 
Gatifloxacin Fluoroquinolone Oral or IV Bactericidal 
Inhibition of 
DNA 
replication 
gyrA: 
DNA gyrase subunit A 
Ethionamide Thioamide Oral Bacteriostatic 
Inhibition of 
mycolic acid 
(cell wall) 
synthesis 
1- inhA: 
Enoyl-ACP reductase 
 
2- etaA/ethA: 
Flavin monooxygenase 
Cycloserine Isoxazolidinone Oral Bacteriostatic 
Inhibition of 
peptidoglycan 
(cell wall) 
synthesis 
Unknown (alrA: D-alanine 
racemase in 
Mycobacterium 
smegmatis) 
Para-
aminosalicylic 
acid 
Salicyclic acid Oral Bacteriostatic 
Inhibition of 
folic acid 
synthesis 
thyA: 
thymidylate synthase 
 
   1.1.2 Emergence of drug resistance: 
 Drug-resistance in tuberculosis could be either initial due to infection with already 
resistant strains or acquired resistance that comes from the selection for resistance due to 
inadequate, interrupted treatment. Acquired resistance can originate also from treatment with 
drugs that the strain already are resistant to; this intensifies the development of resistance to 
even more drugs (Andrews et al., 2008). 
 
Each year, 424,000 individual develop multi-drug resistant TB (MDR-TB), which is 
defined as resistance to at least two of the best first-line anti-TB antibiotics, INH and RIF. 
5 
 
The estimated cure rate with MDR-TB infection ranges between 60-80%, which is to be 
compared to > 95% for fully susceptible strains (Haydel, 2010). MDR-TB infection can be 
fatal even in HIV negative patients due to the lack of a good second-line drug (Leimane et al., 
2005). 
 
This situation had contributed to the promotion of the emergence of extensively drug-
resistant TB (XDR-TB), the definition that was 1st announced in March 2006.  XDR-TB is not 
only resistant to first-line but also to any fluoroquinolone as well as one or more of the 
injectable drugs; kanamycin, amikacin and capreomycin (Gandhi et al., 2006). The number of 
countries that reported at least one case of XDR-TB has jumped from 20 in 2007 to 57 in 
2009, thus highlighting its spread. The cure rate between these patients ranges between 30-
60%. Furthermore, they should be subjected to strict monitoring and support to prevent more 
drug resistance that could make the disease untreatable (Haydel, 2010). In 2012, the third case 
over world of totally drug resistant TB has been diagnosed in India. The first 2 cases were 
discovered in Indonesia and Iran in 2007 and 2009 respectively (Rowland, 2012) 
 
1.2. The urgency of new anti-TB drugs development:  
It is obvious that, the performance of the current stuff for TB diagnosis and treatment 
limits the competent implementation of the DOTS strategy which actually covers only 20 to 
25% of all patients worldwide (O’Brien & Nunn, 2001) (Balganesh et al., 2004).  
 
The two prominent features of the current anti-TB regimen, which makes it far from 
ideal, are combination and long therapy for at least 6 months. The combination therapy is 
mandatory not only to prevent the emergence of drug resistant mutants, but also due to the 
different contribution of the individual drugs in the combination to eradicate the microbe in its 
different states, either rapidly dividing, slow or non-replicating or intracellular (Balganesh et 
al., 2004). The therapy of six months is needed to minimize the risk of relapses produced by 
the persisters, the bacilli that remain in the host for relatively long periods despite appropriate 
drug treatment (Fenhalls et al., 2002). 
 
This kind of lengthy multidrug regimen usually associated with lack of patient 
compliance that   usually leads to emergence of drug resistance. Development of drug 
resistance is frequent when observed treatment is not available, when recommended regimens 
are not used, and with using drugs with poor bioavailability (O’Brien & Nunn, 2001). 
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With the diagnosis of MDR-TB or XDR-TB, the patient will be subjected to very 
expensive regimen schedules consisting of 20 tablets per day and intramuscular injection for 
at least 18 to 24 months. Such regimens are associated with overwhelming, toxic side effects, 
as well as the psychological and social anxieties (Haydel, 2010). 
 
The minimum requirement for a new antituberculosis drug is to decrease the duration 
of therapy. This would enable DOTS to reach higher percentage of patients and to improve 
patient compliance with better control of the disease. The ideal drug to reach this goal would 
be a compound that has cidal activity against replicating and non- replicating bacilli, extra and 
intracellular. When this far goal will be reached, the new compound will be introduced into 
the regimen replacing one or two of the existing members. Studying the 
pharmacokinetic/pharmacodynamic properties of the new compound and also the frontline 
antituberculosis drugs would help to design a more competent dosing regimen that can 
shorten the duration of therapy (Balganesh et al., 2004). 
 
The use of RIF, the most effective drug in reducing patient bacillary burdens for drug-
susceptible TB, is one of the most pressing reasons in new anti-TB drug discovery (Marriner 
et al., 2011). RIF is a powerful inducer of many cytochrome P450 (CYP) enzymes 
particularly P450 (CYP) 3A4. This eventually will inactivate other drugs thus reducing 
effective serum concentrations and exposure. On the other hand, RIF reduces the 
bioavailability of concomitantly administrated drugs by up-regulating  membrane transporters 
(P-glycoproteins) which often work as cellular efflux pumps in the gastrointestinal tract 
(Sousa et al., 2008). RIF might be substituted by rifabutin in HIV-coinfected patients 
receiving antiretroviral drugs whose serum levels are affected by RIF induction of CYP3A4. 
However, current clinical assessment does not completely support substitution of RIF with 
rifabutin (Davies et al., 2007). (Fig. 2) summarizes the desired profiles needed in a new TB 
drug and the characteristic features contributing to achieve these profiles. 
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Fig. (2): Target product profile features needed in the new anti-TB drug and the 
biological characteristics needed to achieve each feature. (Van den Boogaard et al., 2009) 
(Koul et al., 2011). 
 
 
1.3. Tuberculosis drug discovery pathway: approaches and critical issues:  
The process by which a new anti-infective drug is introduced from the laboratory 
bench to the clinical use can be generally classified into two phases. The discovery, or the 
preclinical, phase which includes the laboratory activities up to testing the compound in 
relevant animal models. The second is the development phase which includes testing the 
compound in normal and infected human hosts (Balganesh et al., 2004). The phase of 
discovery has the following major goals:  
 Target identification and validation: this field is markedly enhanced by the 
advanced genomic and proteomic tools and the present era of genome sequencing 
(Wang et al., 2004). Many efforts were done to identify targets which are essential for 
the survival and/or the persistence of the microbe e.g. L-alanine dehydrogenase 
(Hutter & Singh, 1998) and the enzymes involved in the lipid droplet metabolism like 
Ag85A (Elamin et al., 2011) (Stehr et al., 2012). By using comparative genomics, 
targets are evaluated with regard their specificity and selectivity. For more target 
validation, essentiality of targets under different conditions could be evaluated by 
whole cell or animal experiments, gene knock-outs or site directed mutagenesis 
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(Raman et al., 2008). In general, this approach had little success in the development of 
antibacterial agents as the essentiality of a target does not ensure its druggability.  
 Lead identification: to identify compounds those inhibit the biological activity of 
the target molecules leading to cidal or static effect on the microbial growth in vitro. 
The two main approaches that used for lead identification are high-throughput 
screening, and structure based design and virtual screening.   
 Lead optimization: measuring the Pharmacokinetics (PK) of compounds can 
provide an idea about the relationship between the in vitro cidal effects on the microbe 
and the ability to eradicate the microbe from infected animal models. Concurrently the 
therapeutic index, a ratio of the toxic dose to the effective dose, should be monitored 
for reaching an acceptable safety profile. Lead compounds are subjected to synthetic 
and medicinal chemistry for better quality and in vivo potency of the compound 
(Balganesh et al., 2004). 
 
 
 
 
Fig. (3): Tuberculosis drug discovery pathway: Modified from (Nwaka & Hudson, 2006). 
 
 
1.3.1.   High-throughput screening: 
 In modern drug discovery high-throughput screening has an important role. It was 
used over last few years in a large scale to test the inhibitory effect of large numbers of 
compounds either synthesized or naturally purified (Balganesh et al., 2004). It has an 
important role in investigating the viability of small molecules as modulators of a number of 
anti-mycobacterial drug targets. Biochemical high-throughput screening had a major role in 
the finding of two clinical drug candidates, TMC207 and SQ109 (Sacchettini et al., 2008) 
High-throughput screening has two approaches that could be used individually or together:  
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 Whole cell screens (phenotypic screening): which target the whole cell 
growth. During last 10 years, it  has been used to screen millions of compounds to 
derive ‘hits’ that can be used as starting points in the new drug discovery pathway. It 
has the advantage of providing the information about the ability of hits to kill the 
mycobacterium (Nuermberger et al., 2010). Several whole cell screens were 
established like AlarMar Blue redox dye assay (Collins & Franzblau, 1997), 
resazurine microtitre assay (Palomino et al. 2002), luciferase-reporter mycobacterial 
Strain (Lee et al., 2003) and green fluorescent protein based screening systems 
(Changsen et al., 2003) . As this kind of screening is not target or mechanism based, it 
has the hazard of finding compounds that have generalized toxicity (Sacchettini et al., 
2008). As well as the lack of information on the target is considered a rate-limiting 
step in the ability of medicinal chemistry to modify the hits to provide good drug like 
qualities (Nuermberger et al., 2010). 
 Cell-free target-based screens: which predict the inhibitory effect of different 
compounds on a specific target in a cell-free environment. Different assays were 
designed based on the action of purified drug targets (Agren et al., 2008) (Bhuju, 
2009) (Elamin et al., 2009). In this approach it is essential to test the PK profiles of 
these inhibitors, as there are many examples of small molecules that have poor whole-
cell potency in spite of their   excellent target inhibition, most probably due their 
failure to permeate across the mycobacterial cell wall (Sacchettini et al., 2008). 
However, target-specific discovery programs have the advantage of accelerating the 
role of medicinal chemistry to provide compounds that continue to hit the desired 
target as well as better understanding of the mechanism of cell death (Nuermberger et 
al., 2010).  Combining phenotypic and target-based screens might help to avoid the 
drawbacks of each.  
 
1.3.2. Pharmacokinetic studies and drug development: 
PK is the branch which is concerned with the studying of absorption, distribution, 
metabolism, and excretion (ADME) profile of drugs. This field offers better understanding the 
mechanism of action of a new potential drug candidate and at the same time helping in 
decreasing expensive attrition during drug development pathway.  
 
 PK studying and metabolic assessment could be considered crucial in the process of 
drug discovery and development and should be initiated at early stages to achieve the best PK 
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and pharmacodynamics (PD). It is well recognized that good in vitro activity cannot be 
extrapolated to good in vivo activity unless the drug has a satisfactory bioavailability and an 
adequate duration of action (Jiunn & Anthony, 1997). This means that not only the PD that 
control the efficacy and safety but also the PK properties (clearance, half-life, extent of 
protein binding and volume of distribution), the properties that determine the rate and the 
concentration in which the drug will reach its site of action (Panchagnula & Thomas, 2000). 
Many drug candidates were withdrawn from the development pathway due to their 
undesirable PK profile.  In the survey done by (Prentis, et al., 1988), the serious PK troubles 
were 40 % of the causes that lead to drug attrition. So we can emphasize on the corner stone 
role of PK studying to guide medicinal chemistry in the drug design and to accelerate the drug 
development process.   
 
1.3.2.1. Plasma protein binding: 
 Binding to plasma proteins, mostly to albumin and α acid glycoprotein, is profoundly 
affecting the PK and PD of a compound. Thus plasma protein binding (PPB) experiments are 
done essentially during the phase of drug discovery and development.  
 
The importance of determining the PPB of a new potential anti-TB drug is revealed in 
the studies of early bactericidal activity (EBA) which needs free penetration of the substance 
into cavities. An obvious example, the therapeutic margin which is defined as the ratio 
between usual dose and dose at which EBA= 0. It was much smaller in the case of RIF than 
INH although their similar PK. This could be explained by the percentage of unbound part of 
the dose, 15% for RIF and 100% for INH, that can penetrate freely into cavities. This theory 
also can explain the poor results of rifapentine, 2% unbound fraction, when administrated 
with INH in the continuation phase in clinical trials (Mitchison & Davies, 2008). 
 
The fraction of the unbound drug is a major determining factor of all PK profile of a 
substance as follows: 
 Volume of distribution (Vd): 
It is a solid tenet that only free unbound drug can diffuse across membranes, hence 
protein binding can affect distribution of the drug from the vascular compartment to tissues. 
The relation that can be described by the following equation where (Vd) is the apparent 
volume of distribution, (Vp) is the volume of plasma, (Vt) is tissue volume, (Fup) is the 
unbound fraction in plasma and (Fut) is the unbound fraction in tissue.  
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Vd   = Vp + Vt (Fup / Fut) 
 
 From the previous equation we can conclude that Vd increases when Fup incrases and 
decreases when Fut increases. Of course Fut is playing more important role as Vt is much 
larger than Vp. As the measuring of Fut is considered technically difficult, Fup is measured as a 
lieu of Fut depending on the theory of the equilibrium of unbound unionized drug between 
plasma and tissues. And in this case naturally many other considerations should be taken that 
also govern distribution of substances across membranes as ionization, lipophilicity, active 
uptake and secretion and metabolism by tissues (Jiunn & Anthony, 1997) & (Schmidt et al., 
2010).  
 
 Clearance (CL): 
CL is defined as the volume of blood (or plasma) from which a drug is completely and 
irreversibly removed per unit time. Most of drugs are cleared mainly through liver and 
kidneys. Renal clearance (CLrenal) when the substance is cleared by renal filtration can be 
expressed by the following equation where (GFR) is the glomerular filtration rate. 
 
CLrenal = Fup * GFR 
  
 While hepatic clearance (CLhepatic) can be determined by the following equation where 
(Qhepatic) is the liver blood flow, (CLu int) is the intrinsic hepatic clearance based on unbound 
drug concentration. 
 
CLhepatic = (Qhepatic * Fup * CLu int) / (Qhepatic + Fup * CLu int) 
                                              
                                              (Jiunn & Anthony, 1997) & (Schmidt et al., 2010).  
 
Briefly, we can elucidate from the two previous equations that when the substance is 
eliminated through the glomerular filtration, PPB delays its rate of elimination. Similarly, the 
substance which is highly extracted by the liver, PPB decreases CLhepatic. On the other hand, 
when the substance cleared by tubular excretion or its CLhepatic is flow dependent (low 
extracted substances), PPB considered as a depot that supplying the eliminating organ with 
the drug accelerating the rate of its CL (Lindup & L`eorme, 1981) & (Beer et al., 2009). 
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 Finally, for antibiotics particularly, high PPB that reduces the free drug fraction 
reflected in diminished antimicrobial activity. Many studies showed the effect of PPB on the 
minimal inhibitory concentration (MIC) underlying the idea of the in vivo efficacy of a 
substance cannot only predicted from in vitro MIC and plasma level, but determination of the 
extent of PPB is a very important parameter (Schmidt et al., 2008). 
 
There are numerous in vitro methods for the determination of PPB. Equilibrium 
dialysis (ED) is usually considered as the “reference method”. Generally, it is easy, 
inexpensive and accurate. The cell of dialysis composed of two chambers separated by a 
semipermeable dialysis membrane, available in various molecular weight Cutoffs. (Fig. 4) 
shows a schematic presentation of the dialysis cell. The bound fraction can be calculated from 
the following equation where (CB) is the concentration of bound drug, (CT) is the total 
concentration in plasma chamber and (CU) is the concentration in buffer chamber. 
 
CB = CT - CU 
                                                                                            (Beer et al., 2009) 
 
 
 
 
Fig. (4): Equilibrium dialysis for measuring the binding to plasma proteins. 
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1.3.2.2. Hepatic microsomal stability: 
The hepatic microsomal stability (HMS) assay is widely used to rank substances in 
relation to their metabolic stability. Metabolic stability plays a major role in the success of a 
potential drug candidate. It is clear that the first pass metabolism by liver leads to poor 
bioavailability and shortens the half-life (t1/2) of a substance. Early assessment of microsomal 
stability in drug discovery pathway provides the research team with valuable information 
about potential instability of the compounds. This is helpful to find structure–metabolic 
stability relationships and to modify the synthetic strategy accordingly. Typically, hepatic 
microsomal enzymes are used in in vitro microsomal stability assays for estimation of 
intrinsic CL caused by phase-I oxidation (Mondal et al., 2008) & (Di et al., 2003). 
 
1.3.2.3. Pharmacokinetics/pharmacodynamics of antibiotics as           
preliminary indicator of in vivo efficacy: 
In antibacterial drug discovery and with the progress of the field of anti infective 
pharmacology, much concern was directed to the ability to predict the efficacy of a class of 
compounds based on the pharmacokinetic-pharmacodynamic (PK/PD) parameters. This field 
integrates the composite relationship between organism susceptibility to the antibiotic, which 
is usually measured with the MIC, and the patient PK (Van Bambeke et al., 2006).  
 
PK studies describe what the body does with the drug with regard absorption, 
distribution, metabolism, and elimination. And it depends on the measurement of a drug and 
its metabolites in an accessible biologic fluid as blood and urine.  From the resulting 
concentration-time profile when an agent is administrated in vivo, we can calculate different 
pharmacokinetic parameters such as peak concentration (Cmax), the serum t1/2, CL, Vd and area 
under the curve (AUC) that reflects the cumulative exposure to a compound over a given time 
period (Derendorf et al., 2000).  
 
Three main PK/PD parameters (Fig. 5) have been described to provide an indication 
about the antimicrobial outcomes such as bacterial eradication and/or clinical cure, as a 
successful outcome of an antimicrobial agent requires a specific pharmacodynamic interaction 
between this agent and its bacterial target. PK/PD parameters have a potential value as a guide 
to establish dosing regimens for new and old drugs and for new emerging pathogens and 
resistant organisms (Craig, 1998). 
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The first parameter, (T > MIC), is the time during which the concentration of the 
antibiotic remains higher than the level of the MIC. This correlation between the bactericidal 
effects and time is chiefly affected by the t1/2, dosage and frequency of administration. On the 
other hand, (Cmax/MIC) represents the relationship between the bactericidal effects and the 
concentration. It is mainly affected by the administrated dose and the volume of distribution 
of the substance. The third one, (AUC/MIC), combines both time and concentration effects, as 
it reflects the total exposure of bacteria to the antibiotic with regard time and concentration. It 
is directly proportional to the total amount given during certain time period and inversely 
proportional to the drug clearance (Van Bambeke et al., 2006). 
 
 
 
 
Fig. (5): The main three PK/PD parameters affecting antibiotic potency: (A) is the time 
(T) during which the serum concentration of a substance exceeds the minimal inhibitory 
concentration (MIC), (B) is the ratio between the peak plasma concentration (Cmax) and the 
MIC, (C) is the ratio between the area under the concentration-time curve (AUC) for 24 hours 
and the MIC. (Van Bambeke et al., 2006) (McKinnon & Davis, 2004). 
 
 
  1.3.2.4.   Lipophilicity and cell penetration: 
 
 M. tb, in comparison to other gram positive and gram negative bacteria has unique 
membrane architecture with high lipid content. The complex, lipid-rich envelope of M.tb 
provides the bacteria with a barrier that prevents the permeation of a broad range of 
therapeutic agents (Marriner et al., 2011). Susceptibility of M.tb to different antibiotics is 
enhanced by inhibitors of cell wall envelop synthesis (Rastogi et al., 1990).  The special 
structure of mycolic acid and mycolyl-arabinogalactan found in the mycobacterial cell wall 
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contributes to the very poor fluidity of the inner leaflet of the cell wall (Liu et al., 1996). 
Fluoroquinolones, macrolides, rifamycins, and tetracyclines are lipophilic antibiotics. They go 
in the bacteria through the lipid bilayer rather than the inefficient pores of the outer leaflet. 
Within an antibacterial class, the more lipophilic agents have the tendency to be more 
effective against M.tb (Brennan & Nikaido, 1995). 
 
 Lipophilicity significantly impacts ADME/TOX profile of drugs. It is also an essential 
parameter in the development of quantitative structure activity relationship (QSAR) (Kerns & 
Di, 2003).  Lipophilicity is measured by (LogPow), the octanol–water partition coefficient, 
which is defined as the ratio of un-ionized drug distributed between the octanol and water 
phases at equilibrium. Higher LogPow values entail more lipophilicity (Leeson & 
Springthorpe, 2007). Compounds that have moderate lipophilicity (LogPow 1.5-3.5) show a 
good balance between solubility in water and permeability to cell wall. They are ideal for oral 
absorption in addition to low metabolic liability. On the other hand, hydrophilic compounds 
have good solubility, but poor permeability for gastrointestinal tract, and are more susceptible 
to rapid clearance by the kidney (Kerns & Di, 2003).  Compounds with a LogPow more than 
5.0 are more likely to have poor absorption. Such compounds are considered non-drug-like 
and are commonly filtered out in the early stages of drug discovery. However, there are 
examples of compounds that have high LogPow values and can be easily absorbed from the 
gastrointestinal tract. Although Entacapone and tolcapone have high LogPow, they are 
approved drugs and have been clinically tested with satisfactory pharmacokinetic properties. 
Entacapone reach the Cmax after one hour of administration. Dissolution enhancers like 
croscarmellose sodium are used in the formulation of entacapone to improve its solubility 
(Kinnings et al., 2009). 
 
 1.3.3 Animal models and preclinical validation: 
 
Testing new TB drugs in animal models is extremely important as not all functions, 
which are essential in vitro, are essential in vivo (Koul et al., 2011). (Table-3) summarizes 
some of the current experimental animal models and their typical uses (Marriner et al., 2011) 
(Lenaerts et al., 2008). 
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Table (3): Animal models in new anti-TB drug discovery. (Marriner et al., 2011) 
(Lenaerts et al., 2008). 
Model Pathology  Utility  Limitations 
 
Mice Pulmonary pneumonia 
and aggregates of 
leukocytes, spleen, and 
liver, permissive for 
growth 
 
 
 Standard model for drug efficacy 
 
 limited pathology 
 
C57BL/6 or 
BALB/c 
(usually) 
  - PK/PD determinations 
- In vivo toxicity/maximum   
tolerated dose 
- Early bactericidal effect assay 
- Standard therapy assays, regimens 
 
 
  
IFN-g gene 
knockout mouse 
 
 
  Rapid in vivo drug assay 
 
 
  
GM-CSF gene 
knockout mouse 
  Mouse unable to prevent disease 
reactivation 
 
 
  
‘Wayne in vivo’ 
mouse model  
  Mouse inoculated with nonreplicating 
Oxygen-deprived bacilli 
 
 
  
Rats Similar to mice  Accepted PK/PD model  Little additional 
information than mice 
 
 
Zebrafish Necrotizing granuloma 
in embryo  
 Early granuloma formation, high 
throughput 
 
 
 Non-pharmacodynamic 
Guinea pigs Pulmonary, splenic, 
and liver lesions; 50% 
solid, 50% necrotizing 
granulomas 
 
 
 Small size with more similarity to 
human 
 Non cavitating 
 
Rabbits -Limited infection 
with Mtb strains. 
- Pulmonary solid and   
necrotizing lesions, 
cavities. 
 - Extensive secondary 
lesions (M. bovis only) 
 
 
 Pathology including pulmonary, CNS 
system, ocular sites 
 Highly sensitive to GI 
distress from many 
agents 
 
Nonhuman 
primates 
Various presentation 
of lesions in multiple 
organs 
 Similar spectrum of disease and PK 
as in humans. 
 Expensive, difficult 
dosing. 
 
 
The mouse model is considered as the most cost-effective tool. Most data from this 
model have the tendency to be reproduced in clinical studies (Koul et al., 2011). It has played 
a major role to predict the bactericidal and sterilizing potencies of new compounds and 
individual drugs, (Rosenthal et al., 2007) (Andries et al., 2010), to assess the effectiveness of 
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drugs in combination (Nuermberger et al., 2006) , the efficiency of intermittent therapy 
(Dickinson & Mitchison, 1970) and the duration of therapy needed to avoid occurrence of 
relapse (Nuermberger et al., 2004) and PK-PD parameters of different agents (Jayaram et al., 
2003) (Jayaram et al., 2004). Recently, the mouse model was used to recognize bacterial 
targets that could modify the liability of mycobacterial persistence after INH treatment (Dhar 
& McKinney, 2010).  
 
Mouse model does not show the marked heterogenecity of lung pathology observed in 
the human infection (Flynn, 2006).Nevertheless, the results obtained from mouse experiments 
are reliable on the bactericidal and sterilizing activity of existing antituberculosis drugs and 
going with the data from numerous clinical studies. Therefore, it is thought that the mouse 
model can be considered as an indicator of human relapse rates (Nuermberger, 2008) On the 
other hand, mice do not form necrotic or hypoxic granulomas which means mice do not 
develop the latent disease, so it is not the model of choice to test drugs under development 
against latent disease (Shi et al., 2011). Mice can be infected by a variety of routes such as 
intravenous, intranasal inoculation, and by aerosol exposure. One of the main features of 
mouse models that it is not accurately understood to what extent the route of infection affects 
the rate of relapse after drug withdrawal (Koul et al., 2011). 
 
1.4 Pyrazinamide and rifampicin: two frontline anti-TB drugs facing the 
huge challenge of resistance: 
Pyrazinamide and rifampicin are two frontline anti-TB drugs. It is important to point 
out that the combination of PZA and RIF had greatly contributed to shorten the duration of 
therapy. Unfortunately, the resistance to both agents is frequent representing a huge obstacle 
in the treatment of TB. This problem of drug resistance should be solved by intensive efforts 
in drug development.  
 
An additional obstacle in front of PZA is the difficulty to test the susceptibility to PZA 
in vitro. Since the In vitro MIC of PZA varies markedly with pH as well as the growth 
enrichment agent, bovine albumin, alters the pH and seems to bind the drug (Zhang et al., 
2002). This problem might be solved by using target based assays for diagnosis of clinical 
PZA-resistance. 
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1.4.1 Pyrazinamide 
PZA, which is an analogue of nicotinamide, is one of the first line antituberculous 
drugs. It is bactericidal to semidormant M.tb that persists in acidic environments inside 
macrophages, so   it has a remarkable role in the shortening of TB therapy from 9-12 months 
to 6 months and by its introduction in the antituberculous therapy the rates of relapses were 
obviously reduced (Muthaiah et al., 2010). PZA is active against the members of MTB-
complex except M. bovis; the intrinsic resistance to PZA is a characteristic feature of this 
member (Allix-Be´guec et al., 2010). 
 
 1.4.1.1 Mechanism of action: 
Despite the fact that PZA is the most sterilizing anti-TB drug, its mechanism of action 
is still unclear. PZA is a prodrug which is devoid of significant antibacterial activity. PZA is 
transformed into its active metabolite, pyrazinoic acid (POA), by the action of the M.tb 
nicotinamidase/pyrazinamidase (referred to as PncA), the amidase enzyme which is encoded 
by the pncA gene (Petrella et al., 2011). 
 
 
 
Fig. (6 ): Action of PncA enzyme on pyrazinamide and nicotinamide (Zhang et al., 2008). 
 
 
 
After the formation of POA inside Mycobacterium there is no convincing evidence to 
explain the mechanism of action. A theory that has been developed by (Zhang & Mitchison, 
2003) is the most predominant theory.  In this theory, POA behaves as an anion that exits 
from the cell by passive diffusion and an inefficient efflux mechanism. In the acidic 
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environment POA will be protonated into the uncharged HPOA which will permeate 
efficiently back into the bacterial cytoplasm and in the neutral cytoplasm it will dissociate into 
the ionic form. Protons that enter the bacterial cell with HPOA could eventually acidify the 
cytoplasm with subsequent inhibition of the vital enzymes. In addition, HPOA could de-
energise the membrane with disruption of the membrane function. With this theory and by 
applying the Henderson-Hasselbach equation to the weak acid POA (pKa 2.9) we can explain 
the differences in MIC of PZA at different pH. In neutral pH the majority of POA will be in 
the charged anion form which cannot enter cells easily (Salfinger & Heifets, 1988) (Jureen, 
2008). This also explains the greater activity of PZA against old non-replicating bacilli in 
which the passive uptake would remain unchanged while the active efflux mechanism is 
down-regulated (Zhang & Mitchison, 2003). 
 
 
 
Fig. (7): Mode of action of Pyrazinamide. PZA: pyrazinamide; POA: pyrazinoic acid; 
HPOA: protonated POA. (Zhang & Mitchison, 2003). 
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This theory is supported by the results of (Zhang et al. 1999) that showed that the 
efflux blocker reserpin increased the accumulation of POA in M.tb. Also reserpin enhanced 
the susceptibility of M.tb to PZA not POA in the results achieved by (Zhang et al., 
2002).There is another theory which is based on that PZA inhibits fatty acid synthetase I 
(FASI). (Zimhony et al., 2000) using the PZA analogue 5-Cl-PZA and M. smegmatis showed 
inhibition of FASI. However, in PZA-resistant M.tb strains, no mutations in FASI have been 
found.This theory needs to be further investigated as it seems as 5-Cl-PZA and PZA/POA 
may have different drug targets (Zhang & Mitchison, 2003) (Jureen, 2008). 
 
1.4.1.2. Use in clinical treatment of TB:  
PZA when was introduced for the 1st time into clinical treatment of TB in 1952, it was 
found to improve cough and the initial febrile reactions (Cordice et al., 1953). Clinical 
studies-evaluating the action of anti-TB drugs in short course chemotherapy- revealed the 
high sterilizing activity of RIF and PZA and their synergism in reducing the proportion of 
positive 2-month cultures and the rates of relapses after treatment (Mitchison, 1985). Further 
studies showed that the sterilizing effect of PZA decreased after the 1st 2 months of therapy 
(East and Central African/British Medical Research Council, 1986) (Hong Kong Chest 
Service/British Medical Research Council, 1991), this could be due to the inflammation that 
leads to an acid environment in the lesions is usually decreased after 2 months (Zhang & 
Mitchison, 2003). PZA helped to shorten the therapy from 12 to 6 months when was 
combined with RIF (Singh et al., 2006). 
 
Current recommended treatment regimens depend on the combination of INH, with 
RIF and PZA. After the initial high bactericidal activity of INH, RIF and PZA act as the main 
sterilizing drugs which eliminate residual, persisting bacilli. Continuation with PZA after the 
first 2 months is usually not recommended, in spite of its minor role in preventing late failures 
(Zhang & Mitchison, 2003).  
 
The combination of PZA with aminoglycosides as streptomycin can be useful in 
retreatment. Aminoglycosides are more active in an alkaline or neutral pH than at acid pH. 
Such combination would be active against all bacilli regardless the pH of the micro-
environment. Treatment regimen with a combination of PZA, streptomycin and para amino 
salicylic acid was found to be successful in 94% of patients (The East African and British 
Medical Research Counsels, 1971). 
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Using PZA in the short-course studies was not highly hepatotoxic in comparison to the 
earlier studies in which large doses were used and hepatitis was frequent(Girling, 1978). The 
most frequent side effect of PZA is arthritic symptoms due to accumulation of uric acid. 
Intermittent administration (e.g., three times per week) could solve this problem (Ellard & 
Haslam, 1976).  
 
 1.4.1.3 Mechanism of pyrazinamide resistance: 
The lack of nicotinamidase/Pyrazinamidase activity due to mutation in the encoding 
gene pncA seems to be the cause of resistance in the majority of PZA-resistant strains. These 
strains are cross resistant to nicotinamide but not to other antituberculous drugs (Zhang & 
Mitchison, 2003). The transformation of pncA gene into the inherently PZA-resistant M. bovis 
BCG and PZA-resistant M.tuberculosis H37Rv retain PZA-susceptibility to theses strains 
(Scorpio & Zhang, 1996). The mutations of pncA gene are characterized by a very high 
diversity, not like mutations in other drug resistance genes, which has no clear explanation. 
This could be explained that pyrazinamidase (PZase) is a non-essential enzyme and all types 
of mutations in the pncA gene are tolerated without affecting the full virulence of the strain. 
On the other hand no mutations in pncA gene or its promoter region were found in a small 
group of PZA-resistant strains which was PZase-negative, suggesting mutations in an 
unknown pncA regulatory gene. Another rare PZA-resistant group was found to be PZase-
positive with no pncA mutations, indicating a possible alternative mechanism of PZA 
resistance (Cheng et al., 2000). M. smegmatis and M. avium are naturally resistant to PZA due 
to POA active efflux mechanism not due to the lack of PZase activity (Sun & Zhang, 1999). 
 
As the PZA-resistant M. tb is still susceptible to POA, a lot of efforts were directed to 
develop POA precursors that could circumvent the mutations in pncA gene and activated by 
other enzymes like estrase. Increasing lipophilicity of POA by converting POA into esters 
was found to increase the anti-tuberculosis activity in vitro (Cynamon et al., 1992) 
(Yamamoto et al., 1995). The main disadvantage of these compounds is their instability in   
Serum. (Simões et al., 2009) showed that longer side chain of POA esters can improve serum 
stability. 
 
 
 
 
22 
 
1.4.2 Rifampicin: 
 
Prokaryotic DNA-dependent RNA polymerase (RNAP) is a multi-subunit enzyme 
responsible for transcription in bacteria. It is an attractive target for development of 
antibacterial agents as it is crucial for bacterial growth and survival, and shows features that 
make it different from mammalian RNAP. At present, the rifamycins are the only group of 
RNAP inhibitors (RNAPIs) that have been approved for clinical use (Chopra, 2007). 
 
RIF is the most important rifamycin in the treatment of tuberculosis. Other rifamycins 
of importance are, rifapentine, rifabutin, rifalazil, and rifamycin T9 (Aristoff et al., 2010). 
Some of them have higher anti-tuberculous activity than RIF (Sánchez et al., 2011). The 
action of rifamycins is not limited against M. tb but also against gram positive bacteria and 
they are used in the treatment of leprosy (Bujnowski et al., 2003). RIF is a first line anti-TB 
medication and it is a key component of the initial anti-TB regimen. It is most efficient in 
inhibiting actively replicating bacteria. It is not useful only in treating active TB, but also in 
inhibiting latent bacteria; however it is not recommended to be used alone due to high rate of 
resistance (Campbell et al., 2001) (Chao & Rubin, 2010). 
 
1.4.2.1 Mechanism of rifampicin action and resistance: 
The mycobacterial RNAP consists of five subunits. The core enzyme is formed of α, 
α2, β, and β’ subunits. The ω subunit only binds when the polymerisation is initiated and falls 
off when the elongation starts. RIF binds to β subunit however, the core can be still assembled 
to the DNA and the first phosphdiester bonds can be formed RIF blocks further formation of 
transcripts after three or four base pairs and RNA elongation is inhibited (Artsimovitch 
&Vassylyev, 2006). More than 96% of RIF-resistant clinical isolates of M. tb were found to 
have mutations in the 81-bp core region of rpoB gene encoding the β subunit. (Musser, 1995) 
(Valim et al., 2000). These mutations can circumvent RIF binding through steric hinder or 
reduced affinity; also the inhibitory signal of the drug can be distorted through allosteric 
modulation (Artsimovitch &Vassylyev, 2006). 
 
Not all mutations within the 81 bp region display the same level of resistance, 
mutations in codon 526 or codon 531which represent 65-85% of mutations result in high-level 
resistance to RIF with MIC >32µg/ml. However, alterations in codons 511, 516, 518, and 522 
result in strains that have low-level resistance to RIF and rifapentin but remain susceptible to 
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two other rifamycins, rifabutin and rifalazyn (Moghazeh et al., 1996) (Ohno, et al., 1996). 
Rare mutations associated with RIF-resistance have also been found in the amino-terminal 
region of rpoB (Heep et al., 2000) 
 
Approximately 90% of RIF-resistant isolates are also resistant to isoniazid, so RIF-
resistance could be considered a useful surrogate marker for multidrug resistance and 
indicating the urgent need to the second line drugs (Yuen et al., 1999) (Watterson et al., 
1998). 
 
 1.4.2.2 Progress in the development of new RNAP inhibitors: 
 One of the main requirements in any developing RNAPI is to have potential novel 
target sites which are distinct from the RIF-binding site (Chopra et al., 2002). Any novel drug 
candidate designed to replace RIF, it is essential to show activity against RIF-resistant 
mutants (Weissman & Müller, 2010).  
 
Many natural products RNAPI have been discovered. These inhibitors include the 
ripostatins (Irschik et al. 1995), corallopyronins (Irschik et al., 1985), myxopyronins (Kohl et 
al., 1983), zwittermicins (Stabb & Handelsman, 1998), and the pyrrothines, thiolutin 
(Khachatourians &Tipper, 1974) and holomycin (Oliva et al., 2001). 
 
(O’Neill et al., 2000) concluded that thiolutin, holomycin, corallopyronin A, and 
ripostatin A likely interact with sites of RNAP distinct from rifampicin. They did not observe 
cross-resistance with genetically defined rifampicin resistance alleles in Staphylococcus 
aureus and these compounds. The absence of pharmacophoric similarity between these 
compounds and RIF supports also this hypothesis. On the other hand rpoB  mutants were 
cross resistant to sorangicin A. Also the results of (Römmele et al., 1990)  and (Xu et al., 
2005) showed the cross resistance between rifampicin and sorangicin suggesting that 
sorangicin A binding site is closely related to that of RIF  inspite of the difference in their 
chemical structure. 
 
Using a combination of genetic, biochemical and structural approaches, 
(Mukhopadhyay et al. 2008) showed that myxopyronin interacts with the RNAP “switch 
region,” the hinge that mediates opening and closing of the RNAP active center cleft. They 
showed that myxopyronin prevents RNAP to interact with promoter DNA. They proposed 
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that myxopyronin inhibits the initiation of transcription by “jamming the hinge” as it prevents 
opening of the RNAP active-center cleft to permit entry of DNA. The authers provided 
experimental evidence that the structurally related α-pyrone antibiotic corallopyronin and the 
structurally unrelated macrocyclic-lactone antibiotic ripostatin inhibit RNAP through the 
same target and same mechanism. This explained the absence of cross resistance between 
these substances and rifamycins, as the residues involved in the interaction are not related to 
the rifamycins-binding site. 
 
 
    
 
                                                                                                                                                     
 
 
 
 
 
With regard the physiochemical and pharmacokinetic properties, myxopyronin and 
corallopyronin exhibit insufficient physiochemical properties, and they have high serum 
protein binding which reduces their active free part in blood. However the RNAP switch 
Fig. (8): Structure and function of 
bacterial RNAP. The crab-claw-like 
RNAP can open and close by a 30° 
rotation of the larger ß’ subunit (clamp) 
around the switch region (hinge). 
Myxopyronin A blocks transcription 
initiation by jamming the hinge 
(Haebich &Von Nussbaum, 2009).  
Myxopyronin A
Myxopyronin A
Fig. (9): X-ray crystal structure of 
myxopyronin A buried in the switch 
region of bacterial RNAP (Haebich 
&Von Nussbaum, 2009). 
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region is a very attractive drug target, these substances need to be further developed to 
improve their physiochemical and pharmacokinetic properties to meet the requirements of the 
drug (Haebich &Von Nussbaum, 2009). 
1.4.2.3 RNAP assay as a tool: 
RNAP assay can be used as a screening tool to predict the inhibitory effect of different 
substances on RNAP. Historically, there are some assays that used to quantify the activity of 
RNAP. The utilizing radioisotopically tagged ribonucleotides, as prescribed by (Daniel et al., 
1975) (McClure, 1980) (Wu et al., 1997), has the disadvantages of high reagent cost, high 
disposal cost of isotopically tagged materials, short shelf life of isotopes and strict monitoring 
of the laboratory area where isotopes are used. On the other hand, using chemically modified 
nucleotides like fluorescent derivative of nucleotide (Bertrand-Burggraf et al., 1984) (Kozlov 
et al., 2005) (Bhat et al., 2006) or other derivative of nucleotide (Vassiliou et al., 2000) may 
not be as good substrate as the natural nucleotides. (Kuhlman et al., 2004) used the florescent 
RiboGreen dye to detect RNA as an end product of transcription. RiboGreen is enhanced by 
both DNA and RNA, so Dnase digestion and ultrafiltration steps should be added to remove 
the DNA template. For these reasons, (Bhuju, 2009) developed a non radioactive assay in 
which the normal nucleotides were utilized. The assay based on measuring the pyrophosphate 
(PPi) that released as an end product of transcription. It depends on converting PPi using ATP 
sulfurylase into ATP that could be measured by luciferin-Luciferase system.  
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2. Motivation and objectives: 
 Tuberculosis (TB) drug resistance is increasing worldwide with the recent emergence 
of totally drug resistant TB which does not respond to any of the commercial drugs. This is 
emphasizing on the inevitable need to accelerate the anti-TB drug discovery and development 
pathway.  
 
 Pyrazinamide (PZA) and rifampicin (RIF) are two important frontline anti-TB drugs. 
RIF is the most potent sterilizing agent against log phase or semi-dormant bacteria, it works 
through the inhibition of the microbial RNA polymerase (RNAP). PZA is one of the most 
important drugs for anti-TB short course chemotherapy. It could be considered the only drug 
which is bactericidal to dormant mycobacterium tuberculosis (M. tb), its activity increases in 
acidic environment and under the anaerobic conditions, the conditions similar to the 
environment inside macrophages and in necrotic caseous lesions. PZA and RIF when 
combined together they helped to shorten the duration of therapy from 12 to 6 months. The 
widespread of the resistance to these front line drugs underscores the necessity of developing 
alternative agents. These facts highlight the importance of finding PZA analogues that can 
evade the mutations in pncA gene and RNAP inhibitors that can substitute RIF. This work is 
an approach to characterize possible anti-tuberculous agents aimed at generating the essential 
pharmacological database with regard their efficacy, toxicity and PK/PD profile in vitro and 
in vivo.   The objectives of the thesis could be summarized in the following points: 
 
 Evaluation of the in vitro activity of different compounds using two cell-free target-
based screens namely the RNAP and pyrazinamidase (PZase) assays. And to use the 
PZase assay to characterize the role of pncA gene in PZA resistance. 
 Evaluation of the in vitro inhibitory profile of PZA analogues, different RNAP 
inhibitors and a library of compounds against M. tb using whole cell screens. 
 Measurement of the in vitro cellular toxicity of different compounds. 
 Measurement of the acute toxicity of selected compounds in mice. 
 Evaluation the in vivo pharmacokinetic profile of selected substances, calculating 
their pharmacokinetic/pharmacodynamic PK/PD parameters and combining these 
results with the in vitro PK testing.    
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3. Materials and methods: 
Experimental design: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (10): Flowchart outlining overall design of experiments undertaken in the thesis: 
Words in red color represent the methods used. 
In vivo experiments 
 In vitro anti-TB efficacy: MIC with resazurine assay 
 In vitro toxicity profile 
- Cell viability: MTT assay       -   Morphology: ICC 
In vitro experiments 
(C) Random library of compounds
 In vitro anti-TB efficacy: MIC with 
resazurine assay 
 Synergistic effect with ethambutol: FIC 
 In vitro toxicity profile 
- Cell viability: MTT assay 
- Morphology: ICC 
 Chromatographic analysis and quantification 
- PK/PD parameters 
- Bioavailability & PK profiles 
 Expression and purification of PZase (wild 
type & 5 mutants) 
 Optimization and validation of the assay 
Synthesis of pyrazinoic acid (POA) analogues
(A)  Pyrazinamide-resistance and pyrazinamide analogues 
 In vitro anti-TB efficacy: MIC with resazurine assay 
 In vitro toxicity profile 
- Cell viability: MTT assay 
- Morphology: ICC 
- Apoptosis: flowcytometry 
-  Induction of intracellular ROS: DCF assay 
Evaluation of PZase mutations in 
PZA-resistance 
Pyrazinamidase (PZase) assay 
3 POA esters 
Evaluation as prodrugs in (PZase) assay  
(B) RNA polymerase inhibitors (RNAPIs)
RNAP assay 
 Validation of the assay 
 Using the assay to screen the 
inhibitory effect of potential 
drug candidates. 
In vitro efficacy and toxicity 
Acute oral toxicity in mice  PK profile in mice (IV & Oral)   
 Toxicity signs. 
 Cumulative mortality rate. 
 Body weight changes. 
 Histological examination 
3 POA amides 
 PPB: ED. 
 Stability with HME: 
Stability with pooled 
HME. 
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 In order to fulfil the objectives of the thesis, the work was divided into three parts as 
presented in the experimental design (Fig.10). The part that was concerned with the 
pyrazinamide (PZA) resistance and PZA analogues was successfully completed in the 
Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany. 
 
 With regard the work with the RNA polymerase (RNAP) inhibitors, the test 
substances were kindly provided by Lionex GmbH, Braunschweig, Germany. The RNAP 
assay was done in HZI. While testing their in vitro efficacy and toxicity was started in HZI 
and continued in Lionex.  
 
3.1 Synthesis of pyrzinoic acid analogues: 
Three pyrazinoic acid (POA) amides, hexadecylpyrazinamide, tetradecylpyrazinamide, 
dodecylpyrazinamide, were synthesized following the protocol described in (Ley& Priour, 
2002). And three POA esters, hexadecylpyrazinoate, tetradecylpyrazinoate, 
dodecylpyrazinoate, were synthesized according to the literature (Nishimura et al., 2009). The 
scheme of synthesis and the structure of the compounds are shown in figures (11) and (12). 
 
3.1.1 Materials and reactions: 
Chemical reagents for the synthesis of compounds were purchased from Sigma 
(Germany) and used without further purification. Reactions were carried out under argon 
(99.996%) to maintain dry conditions.  
3.1.1.1 Pyrazinoic acid amides: 
A solution of (1.2 mmol) the desired amine, (1-hexadecylamine: 290 mg), (1-
tetradecylamine: 270 mg) or (1-dodecylamine: 223 mg.), was prepared in (5 ml) 
dichloromethane. Then (425 µl, 1.27 mmol) methanolic 3N HCl was added. 1 ml toluene was 
added and then the excess toluene and dichloromethane were evaporated twice to obtain the 
hydrochloric salt of the amine. Pyrazinoic acid (100 mg, 0.8 mmol), 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), (235 mg, 1.2 mmol), N,N-
diisopropylethylamine (DIPEA), (200µl, 1.2 mmol) and 1-hydroxybenzotriazole (HOBt), 
(162 mg, 1.2 mmol) were added to the reaction at 0°C. The reaction mixture was stirred for 3 
h at room temperature, then diluted with dichloromethane, washed with brine, dried over 
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sodium sulfate, filtered and concentrated. Dichloromethane was evaporated completely and 
the reaction products were dissolved in diethyl ether and filtered. 
3.1.1.2 Pyrazinoic acid esters: 
A mixture of pyrazinoic acid (200 mg, 1.6 mmol), and triphenylphosphine (PPh3) (420 
mg, 1.6 mmol) and 0.8 mmol of the desired alcohol, (1-hexadecanol: 190mg), (1-tetradecanol: 
172mg) or (1-dodecanol: 224 µl) was dissolved in 5ml tetrahydrofuran (THF). A solution of 
diethyl azodicarboxylate (DEAD), (325µl, 1.6 mmol) in 2.5 ml (THF) was added to the 
reaction over 15 minutes at 0°C, then the whole reaction was stirred for 2 hours at room 
temperature. The reaction mixture was diluted with ethyl acetate, and was washed with brine, 
dried over sodium sulfate, filtered, and concentrated.  
 
3.1.2 Chromatography  
 
3.1.2.1 Thin layer chromatography (TLC):  
Silica gel 60 F254 sheets, 0.2 mm (Merck, Germany) were used for TLC analysis. The 
solvent system used for TLC was a mixture of hexane:ethyl acetate (4:1). TLC was visualized 
by UV irradiation or stained with Potassium permanganate. 
 
3.1.2.2 Column Chromatography (CC):  
Silica gel 60 (0.063-0.200 mm) (Merck, Germany) was used for column 
chromatography. The solvent system applied for the Silica gel column was a mixture of 
hexane: ethyl acetate (5:1) as eluent. 
 
Each compound was dried under high vacuum and the yield was determined. 1HNMR 
spectra were recorded at 400MHz, and 13CNMR spectra at 100 MHz on a Bruker AM 300 
spectrometer. Chemical shifts are reported in δ (ppm), expressed relative to the solvent signal 
at 7.25 ppm (CDCl3, 1HNMR) and at   75.5 ppm (CDCl3, 13CNMR). Coupling constants (J) 
are given in Hz. HPLC-HRMS data were recorded on a Maxis UHR spectrometer (Bruker 
Daltonics); ionization: ESI, positive mode; scan range: m/z 50-1600; rate 1 Hz; external 
calibration using sodium formate clusters; column 50 x 2.1 mm, Acquity UPLC BEH C-18, 
1.7 µm (Bruker); temperature 40 oC; eluent A: H2O/CH3CN 95:5, 0.1% HCOOH, eluent B: 
CH3CN/H2O 95:5, 0.1% HCOOH, gradient: 5% B for 0.5 min, then to 100% B in 19.5 min; 
flow: 0.6 mL/min. 
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N
N
OH
O
C5H4N2O2
MW: 124,10
H3C-(CH2)11NH2 .HCl
N
N
NH(CH2)11CH3
O
H3C-(CH2)13NH2 .HCl
N
N
NH(CH2)13CH3
O
H3C-(CH2)15NH2 .HCl
N
N
NH(CH2)15CH3
O
EDC, HOBt
DIPEA
EDC, HOBt
DIPEA
EDC, HOBt
DIPEA
C17H28N3O
MW: 291,43
C19H32N3O
MW: 319,48
C21H36N3O
MW: 347,54  
 
 
 
 
 
 
 
Fig (11): Scheme of synthesis of amides of pyrazionic acid: DIPEA: N,N-
diisopropylethylamine; HOBt: 1-hydroxybenzotriazole; EDC: 1-(3 dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride. 
 
Pyrazinoic acid  
Hexadecylpyrazinamide
Tetradecylpyrazinamide
Dodycylpyrazinamide 
33 
 
 
 
 
 
 
 
 
 
 
 
Fig (12): Scheme of synthesis of pyrazionic acid esters: DEAD: diethyl azodicarboxylate ; 
PPh3: triphenylphosphine. 
Dodycylpyrazinoate Pyrazinoic acid 
Tetradecylpyrazinoate 
Hexadecylpyrazinoate 
DEAD
PPh3 
DEAD
PPh3 
DEAD
PPh3 
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3.2 Expression and purification of pyrazinamidase wild type and its 
mutants:  
Mycobacterial 6x His- tagged PZase (Wild type and five mutants from clinical PZA-
resistant strains which were cloned in E.coli BL21 were expressed and purified. The glycerol 
stocks of different clones were kindly obtained from Dr. Sabin Bhuju who had constructed 
these clones during his Ph.D. work in the group of Prof. Dr. Mahavir Singh, Helmholtz centre 
for infection research, Braunschweig, Germany. It is known that, the small His-tag has a 
negligible effect on the protein structure and function.  Protein expression and purification 
were done through different steps as follows: 
 
3.2.1 Auto-induction:  
It was done according to the proprietary protocol from Lionex GmbH, Braunschweig, 
Germany. 3 ml from overnight culture (160 rpm, 37°C) of E.coli BL21 in LB media 
supplemented with 50 μg/ml kanamycin was spread in Qtray (Genetix) containing 200 ml 
APS medium with the same antibiotic to form a lawn culture, and the plates were incubated at 
18°C for 3-4 days. The composition of the LB and APS media are shown in the following 
tables. 
 
          Table (4): Composition of LB medium. 
Tryptone (BD) 
 
10.0 g 
Yeast Extract (BD) 
 
5.0 g 
NaCl 10.0 g 
         Distilled water was added up to 1 L and pH was adjusted to 7.4 
 
          Table (5): Composition of APS medium. 
Difco Select APS Super Broth 
 
                                       49.1 g 
Glyerol (87%) 
 
                                       5 ml 
Distilled water was added up to 1 L and pH was checked between 
6.8-7.5 
 
Agar                             15 g 
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3.2.2 Preparation of cell lysate: 
The following steps were performed in cold conditions or instead in ice. Cells from 
APS plates were collected using cell scrapper, suspended in saline and then centrifuged for 1 
hour at 4000 rpm. Cell pellet was resuspended in an appropriate volume (5 ml for each gram 
cell mass) of 20 mM Tris-HCl buffer, pH 8.0. Cell lysis was carried out by the mechanical 
ultrasonicator (Braun Biotech international GmbH). Maximally 20 ml was sonicated at a time 
for 3 x 2.5 min. with 30 sec. interval. Finally, cell lysate was separated from cell debris by 
centrifugation at 18,000 rpm for 15 min. 
 
3.2.3 Fast protein liquid chromatography (FPLC) : 
For all chromatographic processes, ÄKTA purifier system (GE-Healthcare) or 
Pharmacia LKB system (Pharmacia), were used. All buffers were filtered through 0.2 μm 
membrane filter (Sartorius) and degassed under a negative pressure before use. In the case of 
affinity chromatography (Ni-NTA) and ion exchange, the used column was washed with 2 
times column volume from the eluting buffer to remove any old bound proteins. Before 
loading the sample, the used column was first equilibrated with at least 2 times column 
volume of 20 mM Tris-HCl buffer or 50 mM Tris-HCl buffer in the case of ion exchange.  
 Immobilized metal affinity chromatography (IMAC): The purification was 
performed using Ni-NTA Superflow resin (Qiagen). This technique works by allowing 
the histidine tagged protein to be retained by the immobilized nickel in the column.  
Elution of the retained proteins was done with linear gradient of a buffer containing 
500 mM Imidazole as a competitive molecule. 
 Ion exchange chromatography (Mono Q): In which proteins are separated 
according to their net charge for a high resolution separation.  Proteins were eluted by 
increasing the ionic strength of the mobile phase with a linear gradient of 50 mM Tris-
HCl, 500 mM NaCl pH 7.8. 
 Desalting and buffer exchange: desalting was done in Hi Trap Desalting 5x5 ml 
column (Amersham Bioscience) Packed with Sephadex™ G-25, a gel filtration 
product that separates molecules on the basis of size. In a single step, the sample is 
desalted, exchanged into a new buffer and low molecular weight materials such as 
unwanted salts are removed. 20 mM Tris HCl buffer was used for the buffer exchange.  
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 Gel filtration on a Superdex 200: Gel filtration with Superdex (Amersham 
Biosciences) provides the buffer exchange and separation of protein according to the 
size. 
 
3.2.4 SDS polyacrylamide gel electrophoresis (SDS-PAGE): 
 To check the purity of the separated proteins, SDS-PAGE gel was carried out 
according to (Laemmli, 1970) by separating the denatured proteins according to the size in an 
electrical field. Equal volume of 2X loading buffer (with 1/10 volume DTT) was added to the 
protein sample and incubated at 95°C for 10 min for protein denaturation. PageRuler™ 
Protein Ladder (Fermentas) was run simultaneously to define the molecular mass of the 
separated proteins. At the beginning of electrophoresis, a potential difference of 60 V was 
applied till the proteins accumulate in the stacking gel. Afterwards the potential difference 
was increased to 120 V. 
 
The gel was then stained in coomassie blue solution containing 0.1% coomassie blue, 
10% acetic, 40% ethanol and 50% de-ionized water. The gel in the stain was heated in 
microwave for 1-2 minutes until it just started to boil then was shacked at room temperature 
for 15 min. to fix the stain.  To remove the excess background, the gel was destained in 10% 
ethanol. 
 
3.2.5 Protein concentration measurement: 
  Bradford method (Bradford, 1976) was used to measure the protein concentration 
using the Coomassie PlusTM Protein Assay Reagent (Pierce) and bovine serum albumin (BSA) 
with known concentrations as a standard. 5 μl of protein samples and from each standard were 
mixed with 200 μl Protein Assay Reagent then incubated at room temperature for 5 minutes in 
96 well microplate (Greiner). The absorbance was measured at OD595 with MRXTC 
Revelation (Dynex) using Revelation v4.25 (Dynex). Revelation v4.25 (Dynex) was used to 
generate calibration curve with BSA standards and to calculate the protein concentration of 
the samples. 
 
3.2.6 Protein concentration: 
Vivaspin 6 (Sartorius) was used for the concentration of small amounts of proteins. For 
larger volume of protein, 3K PALL concentrator with stirrer was alternatively used. Pressure 
up to 2.5 bar with nitrogen was applied with stirring at 4°C till suitable volume was achieved. 
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3.3 Cell free PZase assay: 
3.3.1 Principle of the assay: 
 As shown in (Fig. 13), the assay depends on the ability of the POA to interact with 
ammonium ferrous sulphate (NH4)2Fe(SO4)2 and to produce red-orange complex (Allen et al., 
1953). The optical density of the resulting compound is correlating to the amount of the 
liberated POA.  
 
 
 
 
Fig. (13): Schematic Diagram showing the principle of PZase assay (Bhuju, 2009). 
 
 
3.3.2 Procedure: 
The cell free PZase assay was optimized as follows to screen the PZA and the 
synthesized amides with the wild type of PncA and its mutants. The Enzymatic assay of PncA 
was done in volume of 200µl of 100 mM Glycine buffer pH 6.2 with 0-8 mM PZA, 0.875 
μMol (4.4 µM) M. tuberculosis PncA, the amount of the enzymes was increased 5 times for 
mutants with almost no activity. The reaction was carried out in thermocycler at 37°C for 5 
minutes then the enzyme was denaturated at 100°C for 5 miutes. Then 25 µl of ammonium 
ferrous sulphate 100 mM was added. After 10 minutes of incubation at room temperature 200 
µl were transferred to 96 well plate (Greiner). The absorbance was measured at OD450 with 
MRXTC Revelation (Dynex).  
 
3.3.3 Quantification and kinetic calculation: 
A standard curve was done using different concentrations of POA correlating the 
absorbance of the red-orange complex with the concentration of the POA. The rates of the 
reactions were calculated (µM/min) and plotted versus substrate concentrations and kinetic 
constants were obtained by fitting the experimental data to the appropriate rate equations by 
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nonlinear regression (Y = (Vmax * X)/ (Km + X), where X is substrate concentration; Y, the 
enzyme velocity; (Vmax), the maximum enzyme velocity; (Km), the Michaelis-Menten 
constant. The turnover number Kcat was calculated by dividing Vmax over Et where Et is the 
concentration of the enzyme.  The kinetic data were calculated and plotted using GraphPad 
Prism 5.0. 
 
3.4 RNAP assay: 
3.4.1 Principle of the assay: 
 The assay was done as described by (Bhuju, 2009) with few modifications. The assay 
depends on measuring the activity of RNA polymerase (RNAP) through quantification of the 
amount of released pyrophosphate (PPi) as an end product of transcription. PPi is transformed 
by ATP sylfurylase into ATP that could be measured using the Luciferin-Luciferase system. 
To lower the background of the reaction, apyrase is used to degrade the remaining nucleotides 
after the RNAP reaction before converting PPi into ATP   (Fig. 14). 
 
 
Fig. (14): Schematic presentation of the RNAP assay. A, B, C and D represent the 
sequential steps of the assay. NTP: Nucleotides (ATP, UTP, GTP& CTP), PPi:  
Pyrophosphate, APS: adenosine 5´ phosphosulfate, Luc: Luciferin. (Bhuju, 2009). 
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3.4.2 Chemicals used for the assay: 
 
Table (6): Chemicals used for RNAP assay: 
                         Substance        Company 
             
 Adenosine 5′-phosphosulfate sodium salt 
             
                   (Sigma Aldrich) 
Apyrase          (NEB) 
ATP Determination Kit        (Biaffin GmbH) 
ATP Sulfurylase        (NEB) 
CTP, 100mM Solution        (Fermentas) 
GTP, 100mM Solution        (Fermentas) 
UTP, 100mM Solution        (Fermentas) 
ATP, 100mM Solution           (Fermentas) 
Manganese Chloride tetrahydrate        (Sigma Aldrich) 
E. coli RNAP core enzyme        (Biozym) 
Sodium Pyrophosphate Decahydrate             (Sigma Aldrich) 
Rifampicin        (Sigma Aldrich) 
Test compounds            (Lionex) 
 
3.4.3 DNA preparation for the assay: 
pUC18 was purified using Maxi prep according to manufacturer’s instruction. A 
colony of   E. coli Top 10F´ with pUC18 was cultivated in 100 ml LB medium supplemented 
with 100 μg/ml ampicillin. After centrifugation at 6000 x g for 15 min at 4°C,the pellet was 
homogenously resuspended in 10 ml Buffer P1 (Resuspension buffer). Then10 ml Buffer P2 
(Lysis buffer) was added and mixed by vigorously inverting 4-6 times. The mixture was left 
to be incubated at room temperature for 5 min to lyse the cells. QIAfilter cartridge was 
prepared by screwing the cap onto the outlet nozzle of the QIAfilter Maxi cartridge. After the 
incubation period, 19 ml of chilled Buffer P3 (Neutralization buffer) was added and mixed by 
vigorously inverting 4-6 times in order to neutralize the effect of lysis. And to clear the 
bacterial lysate, it was poured into the barrel of the QIAfilter cartridge and left at room 
temperature for 10 min. The cap from the QIAfilter cartridge outlet nozzle was removed and 
carefully inserted into the QIAfilter Maxi cartridge and the cell lysate was filtered. Buffer ER 
(2.5 ml) was added to the filtrate. Mixing was carried out by inverting the tube for 10 times 
and the mixture was incubated on ice for 30 min. equilibration of Qiagen-tip 500 was done by 
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adding 10 ml of Buffer QBT and leaving the column to empty by gravity flow. The filtered 
lysate was applied to the QIAGEN-tip to allow the plasmid to bind to the resin. Unnecessary 
contaminants were removed by washing the QIAGEN-tip with 30 ml of Buffer QC (Wash 
buffer). Elution of bound DNA was done with 15 ml of Buffer QF (Elution buffer). The 
eluted DNA was precipitated by adding 10.5 ml of isopropanol. After centrifugation at 15,000 
x g for 30 min at 4°C, the supernatant was decanted. The DNA pellet was washed with 5 ml 
of 70%ethanol and the supernatant was decanted after centrifugation at 15,000 x g for 10 min. 
The pellet was air-dried and the DNA was redissolved in 500 μl distilled water.  
 
The size of the plasmid was determined by analysis on 1% or agarose gel. Agarose 
was dissolved in 1x TAE buffer. DNA was loaded with 6-fold loading buffer (Fermentas) 
onto the gel using 1 x TAE as running buffer. The electrophoresis was performed at 80 - 100 
Volts for 30-45 minutes. The agarose gel was stained in a GelStar Nucleic Acid Stain (Lonza 
Verviers) in 1x TAE for 10 min. DNA was visualized using Dark Reader transilluminator 
(Clare Research) and Photography of the agarose gel was done under UV light with Fluor-S 
MultiImager (Bio-Rad ). The DNA concentration was measured using Qubit quantification 
fluorometer and Quant-iT reagents (Invitrogen) and finally, the concentration was adjusted to 
250µg/ml. 
Table (7): Composition of 50X TAE buffer. 
Tris-Base  242 g  
 
Glacial acetic acid  57.1 ml  
 
0.5 M EDTA (pH 8.0)  100 ml  
 
Water up to  1000 ml  
 
 
3.4.4 Procedure of the assay: 
1) ATP alone was measured with the Luciferin-Luciferase system as the first standard 
method (using ATP 1nm, 10nm, 100nm, 1µM, 10µM solutions). 
2) The ability of ATP Sulfurylase to utilize PPi and convert it into ATP was confirmed 
by using PPi as a substrate: The positive reaction contained 10 μM of PPi, 5 μM 
adenosine-5´ phosphosulfate, 30 mU ATP Sulfurylase. The positive reaction was 
repeated with the presence of RIF 10 µg/ml and in the negative reaction, PPi was 
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excluded. The reaction was run in a thermocycler for 10 min at 30°C. Then 
denaturation of the enzyme was performed at 85°C for 10 min. lastly net ATP 
produced during the whole reaction was measured using ATP kit. 
3) The whole assay was performed as follows (all incubation and denaturating steps were 
carried in a thermocycler : 
 The RNAP reaction mixture contained 2U of E. coli RNAP core enzyme, 500 
ng pUC18 plasmid DNA in 10 mM MgCl2, 1.5 mM MnCl2, 0.1 mM EDTA, 
50 mM NaCl, 20 mM Hepes, pH 8.0 and 25 μM of each NTPs (ATP, UTP, 
GTP and CTP). The DNA was excluded in the negative reaction and the 
positive control is repeated with the presence of RIF 10 µg/ml. The mixture 
then incubated for 30 minutes at 37°C for RNAP to synthesize RNA. This 
results in at least 90% maximal RNA synthesis (Kuhlman et al. 2004).   
 50 mU of apyrase was added to degrade the residual NTPs present in the 
reaction mixture. The reaction was carried out for 15 min at 30°C. Then 
denaturating of the enzyme was done for 10 min at 85°C.  
 (APS) adenosine-5´-phosphosulfate (15 μM) and ATP Sulfurylase (30 mU) 
were added to transform PPi into ATP. This step was carried out for 15 min at 
30°C.  
 A final denaturating of the enzymes present in the whole reaction was 
performed at 85°C for 10 min.  
 Finally, the amount of ATP produced during the whole reaction was evaluated 
with ATP kit (Biaffin GmbH). ATP catalyzes the conversion of luciferin into 
oxyluciferin with production of visible light. 
  Luminance was measured with POLARstar OPTIMA (BMG Labtech) in half 
area white plates (Costar). The relative light unit detected from a reaction 
mixture corresponds to the amount of ATP present in the reaction mixture, 
which reflects the amount of PPi produced during the polymerization reaction 
of RNAP. 
4) The whole assay was repeated with the presence of different concentrations of the test 
compounds. 
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3.5 Minimal inhibitory concentration (MIC): 
 The minimal inhibitory concentrations (MICs) of the substances were determined 
using   resazurin microtiter assay (REMA) as described by Palomino (Palomino et al., 2002) 
in 96 well microplate. Mycobacterial strains were kindly provided by Lionex GmbH, 
Braunschweig, Germany. Resazurin is a blue dye, itself nonfluorescent until it is reduced to 
the pink colored and highly red fluorescent resorufin by living cells. Resazurin sodium salt 
powders (Sigma) were prepared at 0.01% (wt/vol) in distilled water and filter sterilized. It was 
stored at 4°C and used within 1 week. The assay was performed in 7H9 medium (BD) 
supplemented with 10% ADC enrichment medium (Fluka), 0.2% glycerol (Roth), 0.02% 
Tween-80 (Sigma).  
  
Two-fold serial dilutions of the tested compounds were prepared in 96 well plates in 
7H9 medium with volume 100µl. When the bacteria reached early exponential phase (OD550 
=0.3), it was sonicated in ice bath for 30 sec and then diluted 1:20, and 100 µl was used as an 
inoculum. Growth controls containing no antibiotic and sterility controls without inoculation 
were also included. The plates were covered, sealed, and incubated at 37°C in the normal 
atmosphere. After 7 days, 30 µl of resazurin solution was added to each well and the plates 
were further incubated overnight at 37°C. The change of color was assessed; a change from 
blue to pink indicated reduction of resazurin and thus bacterial growth. The MIC is defined as 
the lowest substance concentration that prevents this color change. Dose-response curves 
were drawn by measuring the florescence in black plates with excitation at 560nm and 
emission at 590nm. 
 
To determine the effect of protein binding on the in vitro MIC, the test was performed 
in medium that contains 50% fetal bovine serum (FBS). 
 
3.6 Assessment of in vitro cellular toxicity profile: 
Cell lines and media: 
Cell lines were kindly provided by Dr. Florence Sasse, Helmholtz Center for 
Infection Research, Braunschweig, Germany. L-929 and J-774A.1 cells were also provided 
by Lionex GmbH, Braunschweig, Germany.  Cells were grown at 37°C and 10% CO2 in 
the following media: 
- L-929 cells (mouse connective tissue fibroblast), J-774A.1 (mouse monocytes-
macrophages), HEPA 1-6 cells (mouse hepatoma), KB-3-1 (human cervix 
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carcinoma):  Dulbecco’s modified Eagle's medium (DMEM), Lonza 
-  PtK2 cells (rat kangaroo kidney epithelial cells): Minimum Essential Medium 
(MEM) medium, supplemented with 1 % non-essential amino acids and 1 % 
glutamax, Invitrogen. 
- U-937 (human histiocytic lymphoma): Roswell Park Memorial Institute medium 
(RPIM 1640), Invitrogen 
-  HUVEC cells (human umbilical vein endothelial cells): endothelial basal medium 
(EBM-2), (Lonza) supplemented with endothelial growth medium 2 (EGM-2) kit 
(FCS, hydrocortisone, hFGF-B, VEGF, R3-IGF-1, ascorbic acid, hEGF, GA-1000, 
heparin) 
 
All media were supplemented with 10 % fetal calf serum except for HUVEC cells 
it was 5% (Lonza or Gibco). 
 
Table (8): Apparatus & materials used for cell culture       
           Item     Details 
             
 Incubator 
             
                   CO2-Auto-Zero, Thermo Scientific 
Microscope         Axiovert 35, Zeiss, Germany 
Hemocytometer        Neubauer improved, Assistent Germany 
Multi-plate reader        Wallac, 1420 Victor Multilabel Counter 
Vortex        Heidolph, REAX 1 R, Germany 
Digital multichannel Pipette        Matrix Technologies Corp, Thermo Scientific
FacScan        BD LSR II 
Flourescent Microscope        Zeiss, Germany 
96 well plates        Falcon, Becton Dickinson, USA 
Scraper        Nalge nunc international, nunc, USA 
Resevoir        Carl Roth, Germany 
4-well plates        Nalge nunc international, nunc, USA 
Round cover slips            Thermoscientific 
Trypsin        Invitrogen 
0.25 % trypsin/EDTA        Invitrogen 
Earle's balanced salt solution        Gibco 
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3.6.1 In vitro toxicity testing: 
 The effects of the tested compounds on cell proliferation and the acute toxic effects 
were assayed in vitro on different mammalian cell lines. The metabolic activity was measured 
by means of (MTT) cell survival colorimetric assay. MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide) is a yellow dye that was used to measure the metabolic 
activity of cells which are capable of reducing it by dehydrogenases to a violet formazan 
product. 
 
Solutions:  
- Phosphate buffered saline (PBS): 
PBS solution (pH = 7.45) was prepared by dissolving one PBS tablet (Gibco) in 500 ml 
distilled water. 
- Acidified  isopropanol: 
0.4 ml of concentrated HCl was added to 100 ml isopropanol.  
- (MTT) dye: 
1 g of MTT (98%, Sigma Aldrich) powder was dissolved in 200 ml of PBS and used 
directly without dilution. It was stored below 4°C, in the dark and was used within two 
weeks. 
 
Steps: 
A) Effect on proliferation: 
60 μl of serial dilutions of the test compounds were added to 120 μl aliquots of a cell 
suspension (50,000 cells/ml) in 96-well microplates then incubated 5 days at 37°C and 
10% CO2. 20 µl MTT dye were added to a final concentration of 0.5 mg/ml. After 2 h the 
precipitate of formazan crystals was centrifuged, and the supernatant discarded. The 
precipitate was washed two times with 100 µl PBS and dissolved in 100 µl of the 
acidified propanol. The plates were stirred for 20 minutes on a microtitre plate shaker. The 
resulting colour was measured at 590 nm using a multi-plate reader.  
B) Acute toxic effect: 
When a substance showed an anti-proliferative effect, the acute toxic effect was 
evaluated as follows.120 µl aliquots of a cell suspension (100,000-200,000 cells/ml) in 96-
well microplates were incubated at 37°C and 10% CO2 and allowed to grow for two days to 
stop the cell propagation. Then 60 µl of serial dilutions of the test compounds were added 
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and incubated for further 24h. After 24h incubation at 37°C and 10% CO2 the MTT assay 
was performed as described before.  
 
All investigations were carried out in two parallel experiments. Results of cytotoxicity 
assays were expressed as the percentage of cellular viability. The IC50 values were 
determined as the concentrations of tested compounds, at which cell samples developed 50% 
of the absorbance of untreated control cells as estimated from the dose-response curves (Sigma 
Aldrich protocols) (Shaaban, 2010).  
3.6.2 Immunocytochemistry (ICC): 
The effects of substances on the phenotypical changes of cell shape and adhesion were 
investigated by the technique of immunocytochemistry (ICC). ICC is a technique used to 
assess the presence of a specific protein or antigen in cultured cells by using a specific primary 
antibody, which binds to this protein. And by using a florescent labeled secondary antibody, 
cells can be visualized under microscope. By this method we can visualize different structures 
in the cell as the endoplasmic reticulum (ER), microtubules and actin stress fibers. And by 
staining normal controls of untreated cells we can predict the morphological changes that could 
be produced by treatment with different substances (Immunocytochemistry Methods, 
Techniques & Protocols).  Actin filaments, microtubules and the ER were investigated upon 
treatment of the potoroo cells (PtK2) cells with/without test compounds.  
Reagents: 
- Ice cold MeOH/acetone (1:1)  
- Paraformaldehyde, Sigma aldrich:  3.7 % in PBS  
- PBS   
- Triton X-100, Sigma aldrich: 0.1 % in PBS 
-  Anti-fade solution with DAPI, (Invitrogen)  
- Primary and secondary antibodies  
Procedure: 
PtK2 cells were grown on cover slips in 4-well plates. semi-confluent cells were treated 
with test compounds and the plates were incubated over the night. According to the type of 
the antibody that will be used, the cells were fixed either with cold methanol /acetone for 10 
min or with 3.7% paraformaldehyde for 10 min followed with Triton X-100 (0.1%) for 5 min.  
Then the cells were washed with PBS and the primary antibody was added and incubated for 
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45 min and washed with PBS. Secondary antibody was then added to the cells and incubated 
for additional 45 min.  After washing with PBS, Cover slips were mounted in anti-fade 
mounting medium with DAPI. Images were taken with a CCD camera attached to a 
flourescence microscope. The following antibodies were used:  
- endoplasmic reticulum (after MeOH/acetone fixation) 
o Primary antibody: anti GRP-94,  thermoscientific 
o Secondary antibody : Alexaflour goat anti-rat 488, Invitrogen 
 
- tubulin (after MeOH/acetone fixation) 
o Primary antibody: α-tubulin, (Sigma) 
o Secondary antibody: Alexaflour 488 anti-mouse, (Invitrogen)               
 
- Actin; (after formalin-triton X-100 fixation)   
o Phalloidin Ph594, (Molecular probe) 
 
 
3.6.3 Induction of apoptosis (Double-labeling assay with annexin-V and PI): 
Apoptosis were assessed by flow cytometric analysis of U937 cells treated for 12 h 
with test compounds using the FITC Annexin V Apoptosis Detection Kit II (BD Pharmingen). 
Annexin V has a high affinity for the membrane phospholipid phosphatidylserine (PS). In the 
early stages of apoptosis, PS is translocated from the inner to the outer leaflet of the cell 
membrane due to loss of membrane symmetry. Propidium Iodide (PI) is used to differentiate 
viable from nonviable cells as it cannot pass through the membrane of viable cells (BD 
Bioscience data sheets).  
 
Assay procedure:  
U937 cells (106/experiment) were treated with different concentrations of test 
compounds. After 12 hours incubation, they were suspended in 1 ml binding buffer.     
100 μl of the cell suspension were stained with a mixture of 5 μl FITC Annexin V and 5 
μl PI. After 15 min of incubation in dark, 400μl of binding buffer was added and the 
samples were analyzed after further 30 min by FacScan.  
 
3.6.4 Dichlorofluorescein assay (DCF): 
 DCF assay was used as a general indicator of intracellular reactive oxygen species 
(ROS) formation. The DCF assay is sensitive to H2O2, ONOO- and lipid hydroperoxides. It is 
also used to predict the production of O2.- which is transformed rapidly into H2O2. 2`,7`-
dichlorodihydrofluorescein diacetate (DCFH-DA) is a cell-permeable non-fluorescent probe. 
It is de-esterified intracellularly into non-fluorescent 2`,7`-dichlorodihydrofluorescein 
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(DCFH).  The later turns to highly fluorescent 2′,7′-dichlorofluorescein upon oxidation (Fig. 
15).(Karlsson et al., 2010) (Xu & Lu, 2010). 
 
 
 
Fig (15): Detection of ROS with the DCFH-DA probe: DCFH-DA is cleaved by 
intracellular esterases to DCFH and oxidized by ROS to the highly fluorescent molecule DCF. 
 
Assay procedure 
30 mM DCFH-DA stock solution was prepared by dissolving 2´,7´- 
dichlorodihydrofluorescein diacetate (50 mg, 97%, Sigma Aldrich) in 3.4 ml DMSO. 
 
HEPA 1.6 were seeded in a black-walled 96-well plate at a density of 105 cells per 
well in DMEM medium supplemented with 10% fetal bovine serum.  Cells were treated with 
different concentrations of the test compounds for 1 hour. Then 20 µl of 10 µM DCFH-DA 
was added to each well and the plates were incubated in dark for 30 minutes.The intensity of 
fluorescence was measured immediately by a spectrofluorophotometer at excitation and 
emission wavelengths 485±20 nm and 528±20 nm respectively. Results were expressed as 
arbitrary units of fluorescence (Au) per 105 cells (Shaaban, 2010). 
 
3.7 In vitro pharmacokinetics: 
3.7.1 Hepatic microsomal stability and 1st pass effect: 
Pooled mouse microsomes (protein concentration, 20 mg/mL) were purchased from 
XenoTech (Lenexa, KS). NADPH was purchased from Sigma. Compound stock solution was 
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prepared in DMSO. The final concentration of DMSO in the reaction was 0.2% (v/v). The 
stability of LX079 in microsomes was determined after their incubation at 1 µM with mouse 
liver microsomes (0.5 mg/mL) in 50 mM potassium phosphate buffer (pH 7.4) at 37 °C. The 
total incubation volume was 100 µL. The reaction mixture was prewarmed at 37 °C for 5 min 
before adding NADPH (1.0 mM). Reactions were quenched at 0, 5, 10, 15, 20, 30 min by 
adding acetonitrile (300 µL). For control experiments, NADPH was omitted from these 
incubations. The samples were filtered using miniuniprep filter PTFE 0.2 µM (Whatman) and 
then analyzed with UHPLC/MS. The hepatic intrinsic clearance was estimated by scaling up 
the in vitro t1/2.  
 
3.7.2 Equilibrium dialysis for plasma protein binding: 
 The rapid equilibrium dialysis device (RED) was purchased from thermoscientific 
with cutoff-mass of dialysis membrane 8,000 daltons. Pooled mice plasma was prepared by 
K3EDTA and by centrifugation for 10,000 for 2 min. The substance was prepared at a 
concentration of 1µM and 2 µM in plasma and the organic content was kept below 1%. 300µl 
plasma was dialyzed against 500 µl PBS at 37°C for 4 hours. The dialysis device was sealed 
properly and vortexed 500 rpm on a plate vibrator for achieving equilibrium. Nonspecific 
binding to the membrane was excluded by running control experiments with buffer in the both 
chambers. At the end of dialysis 100 µl of plasma and buffer was collected and precipitated 
with 300µl acetonitrile. The samples were filtered using miniuniprep filter PTFE 0.2 µM 
(Whatman) and then analyzed with UHPLC/MS.   
  
For determination of the degree of binding to hepatic microsomal enzymes, 2µM of 
the substance was prepared in pooled hepatic microsomes diluted to 1mg/ml in PBS and then 
100µl of pooled hepatic microsomes was dialyzed against 300µl PBS.  
 
3.8 In vivo studies:   
All animal procedures were approved and supervised by the Animal Care Committee 
of the Germans Trias i Pujol University Hospital and by the Department of Environment of 
the Catalan Government (approval number 4095). Mice were weighed and checked according 
to the protocols and observation data sheets that were requested. Animals were followed for 
weight loss, apparent good health (bristled hair and wounded skin) and behaviour (signs of 
aggressiveness or isolation).  
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3.8.1 Animals: 
 Young adult (6-8 weeks old) female C57/BL6 mice, 20 mice for acute oral toxicity 
testing and 81 mice for pkarmacokinetic experiment were used. The animals were nulliparous 
and non-pregnant weighing 20 ±1.5 g each. They were maintained in their cages provided 
with a standard laboratory rodent diet and unlimited supply of drinking water and were 
allowed to acclimatize to the laboratory conditions for seven days before starting the 
experiments. The temperature in the experimental animal room was kept at 22°C ± 3°C and 
the relative humidity was 50 ± 20 %. Lighting was artificial with the sequence 12 hours light 
and 12 hours dark.  
 
3.8.2 Substance formulation for in vivo model: 
 Doses were prepared in 5% DMSO in sterile water for oral dosing through oral gavage 
at a dose volume of 0.3 ml, and in 5% DMSO in PBS, pH 7.4 for IV bolus injection via tail 
vein at a dose volume 0.1 ml.  
 
3.8.3 Testing of acute oral toxicity in mice: 
The oral acute toxicity study was carried out using 20 mice that were randomly 
distributed into one control group and 3 treated groups, containing five animals per group.  
The control group received the vehicle while each treated group received the substance at 
doses 62.5, 125 or 250 mg/kg as a single oral dose. The animals were observed continuously 
for the first 4 h and then daily for the following 14 days, to observe any death or changes in 
general behavior and other physiological activities. Animals were weighted at the time of 
dosing then after 1 week and at the end of the experiment. Animals were observed for 
morbidity conditions, pain, skin, fur, respiratory distress, allergic reactions, eyes, salivation, 
diarrhea, behavior (hypo-hyper reactivity), tremors, convulsions, ataxia, lethargy or coma. At 
the end of the experiment mice were sacrificed and the internal organs were observed for the 
presence of any gross necropsy, the histopathology was done for the liver, spleen, lungs and 
kidneys in the control and highest dose groups. The cumulative mortality rate was calculated 
using Reed–Muench method (Reed &Muench, 1938). 
 
3.8.4 In vivo pharmacokinetics: 
For studying the PK profile of the LX079, 81 mice were used each received single 
dose either oral or IV. The animals were divided into one IV group (27 mice), 2 oral groups 
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(24 mice each), control IV group (3 mice) and control oral group (3 mice). The IV group and 
one oral group were dosed with 12.5 mg/kg and the other oral group was dosed with 25 
mg/kg, while the control groups received the vehicle. All blood samples were collected at 15 
and 30 min and 1, 2, 4, 6, 8, and 24 h after oral dosing, and at 5, 15, and 30 min and 1, 2, 4, 6, 
8, and 24 h following intravenous administration. The blood was collected from the control 
groups at 24 h. Mice were euthanized with isoflurane and a 0.3 mL aliquot of blood was 
collected via terminal bleed from three mice at each time point. Blood samples were collected 
in heparin as anticoagulant and plasma was harvested by centrifugation at 10,000 rpm for 2 
minutes. Plasma samples were kept at -80 °C until analysis.  
 
3.9 UHPLC/MS analysis: 
For quantification, calibration standards for LX079 were prepared in normal mice 
plasma by two-fold serial dilutions. After protein precipitation and filtration as described 
above, the parent substance was quantified in the samples using LC/MS in the cooperation 
with Knauer GmbH, Germany. 
 
The LC-MS analysis was performed using PLATINblue UHPLC-MSQ system 
(Knauer, Germany). Reversed phase liquid chromatography separations during LC-MS were 
carried out by using BlueShell 80-2.6 C18, 100 x 2 mm ID column connected to the UHPLC 
system. The LC separation was performed using a binary gradient consisted of a mixture of 
0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B). The 
gradient (at flow rate of 0.6 ml/min) was programmed as follows: 0 - 2 min (40 % B), 2 - 2.2 
min (40 - 100 % B) and 2.2 - 3 min (100 % B). The column temperature was 35°C and the 
injection volume was 5 µl.   A full scan in the range of 20 – 1000 m/z was performed to find 
the mass of the target compound. The highest signal was reached for m/z = 490 and it was 
chosen for quantification. The electrospray ionization (ESI) was conducted in the positive 
ionization mode with needle voltage 4 KV and cone voltage 75 V. The capillary temperature 
was 500°C.  
 
3.10 Pharmacokinetic analysis:   
The area under the 24 hours plasma concentration-time curve (AUC) was calculated 
using the linear trapezoidal rule. Following IV bolus administration, half-life (t1/2) and plasma 
clearance (CL) were calculated using the following equations where K is the elimination rate 
constant of the one phase decay (Shahab et al, 2010). 
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t1/2 = 0.693 / K 
 
CL = Dose / AUC 
 
Following oral dosing, absolute bioavailability (F) was calculated from the following 
equation where (AUCPO) and (AUCIV) are the areas under the 24 hours plasma concentration-
time curves following oral and IV administration respectively (Shahab et al, 2010). 
 
F = (AUCPO / AUCIV ) * (doseIV / dosePO ) 
 
The in vitro stability with the hepatic microsomal enzymes was calculated as follows:  
 
Stability (%) = 100 x Conc. at 30 min / Conc. at 0 min 
 
The In vitro t1/2 was calculated from the following equation, where K is the 
elimination rate constant obtained from the slope of disappearance kinetics (in the form of 
relative remaining concentration of the parent substance versus time). 
 
t1/2 = 0.693 / K 
 
The In vitro clearance (CLint, inc) was calculated from the equation: 
CLint, inc = k * (V/M) / Fub 
Where V is the volume of incubation, M is the amount of microsomes in the incubation 
and Fub is the unbound fraction. Fub was calculated from the results of the equilibrium dialysis 
as follows: 
Fub = Conc. in buffer side / Conc. in side of microsomes 
The hepatic intrinsic clearance CLint from microsomal incubation in turn was calculated 
as:  
CLint = CLint,inc * MPPGL * weight of liver 
Where MPPGL is the scaling factor for microsomal protein per gram of liver (Davies 
& Morris, 1993) (Nassar et al., 2009) (Houston, 1994) (Naritomi et al., 2001) 
(www.admescope.com) (www.cyprotex.com). 
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4. Results 
 
4.1 Pyrazinamide resistance and pyrazinamide analogues: 
4.1.1 Synthesis of pyrazinoic acid analogues: 
4.1.1.1 Pyrazinoic acid amides: 
Three pyrazinoic acid (POA) amides, N-dodecylpyrazinamide, N-
tetradecylpyrazinamide, N-hexadecylpyrazinamide, were synthesized to be evaluated in the 
pyrazinamidase assay and to be compared with pyrazinamide. The three amides were 
synthesized following the method described by (Ley & Priour, 2002). In this synthesis we 
succeeded to obtain good to excellent yields of the desired amides (47-97%) in comparison to 
the yield ( less than 55%)  obtained in the method used by (Simões, et al. 2009) when they 
synthesized the same pyrazinoic acid amides.   
 
N-Dodecylpyrazinamide: 
White solid; TLC hexane:ethyl acetate (4:1), rt 0.13; yield 46.8%; 1H NMR (400 MHz, 
CDCl3) δ 0,89 (3H, t, J = 6.6 Hz), 1.23–1.45 (18H, m), 1.60–1.70 (2H, m), 3.50 (2H, m), 7.83 
(1H, sbroad), 8.54 (1H, dd, J = 2.4, 1.2 Hz), 8.76 (1H, d, J = 2.4 Hz), 9.43 (1H, d, J = 1.2 Hz); 
13C NMR (100 MHz, CDCl3) δ 14.14, 22.70, 26.98, 29.31, 29.35, 29.54, 29.58, 29.59, 29.64, 
29.65, 31.92, 39.51, 142.46, 144.43, 144.62, 147.15, 162.85; MS +H+, 301.4. 
 
N-Tetradecylpyrazinamide: 
White solid; yield 96%; TLC hexane:ethyl acetate (4:1), rt 0.13;  1H NMR (400MHz, 
CDCl3) δ 0.89 (3H, t, J = 6.6 Hz), 1.24–1.46 (22H, m), 1.60–1.70 (2H, m), 3.50 (2H, m), 7.83 
(1H, sbroad), 8.34 (1H, s), 8.76 (1H, s), 9.43 (1H, s); 13C NMR (100 MHz, CDCl3) δ 14.14, 
22.70, 26.98, 29.31, 29.35, 29.37, 29.54, 29.58, 29.60, 29.66, 29.68, 29.69, 31.93, 39.51, 
142.46, 144.43, 144.62, 147.15, 162.85; MS +H+, 329.48. 
 
N-Hexadecylpyrazinamide: 
White solid; yield 96.8%; TLC hexane:ethyl acetate (4:1), rt 0.13;  1H NMR (400 
MHz, CDCl3) δ 0.90 (3H, t, J = 6.8 Hz), 1.23–1.47 (26H, m), 1.67 (2H, m), 3.50 (2H, m), 
7.83 (1H, sbroad), 8.54 (1H, dd, J = 2.4, J = 1.2 Hz), 8.77 (1H, d, J = 2.4 Hz), 9.44 (1H, d, J = 
1.2 Hz); 13C NMR (100 MHz, CDCl3) δ 14.15, 22.71, 26.98, 29.32, 29.38, 29.55, 29.58, 
29.61, 29.66, 29.67, 29.68, 29.69, 29.70, 31.94, 39.52, 142.47, 144.44, 144.62, 147.16, 
162.92; MS +H+, 357.54. 
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4.1.1.2 Pyrazinoic acid esters: 
Three POA esters, dodecylpyrazinoate, tetradecylpyrazinoate, hexadecylpyrazinoate, 
were synthesized. The aim was to evaluate the possibility if these esters could be an 
alternative to pyrazinamide (PZA) in a trial to circumvent the mutation in PncA, the most 
common cause of PZA resistance. The three esters were synthesized by Mitsunobu reaction 
described in (Nishimura et al., 2009). The three esters were synthesized by reactions of POA 
with the corresponding alcohols in the presence of diethyl azodicarboxylate (DEAD) and 
triphenylphosphine (PPh3) in tetrahydrofuran (THF). By this method and with the results of 
(Nishimura et al., 2009), the reaction proceeded completely by adding a solution of (DEAD) 
in (THF) slowly at 0°C to the mixture of the alcohol, pyrazinoic acid, and (PPh3) in (THF) 
before leaving the reaction to proceed at room temperature. In this synthesis we succeeded to 
obtain excellent yield of the desired esters (100%) in comparison to the yield (less than 50%) 
obtained in the method used by (Simões et al. 2009) when they synthesized the same 
pyrazinoic acid esters.   
 
Dodecylpyrazinoate: 
Waxy white solid; TLC hexane:ethyl acetate (4:1), rt 0.22; yield 100%; 1H NMR (400 
MHz,CDCl3) δ −0.81 (3H, t, J = 6.6 Hz), 1.22–1.40 (16H, m), 1.45 (2H, m), 1.84 (2H, m), 
4.45 (2H, t, J = 6.4 Hz) 8.75 (1H, dd, J = 2.4, 1.2 Hz), 8.78 (1H, d, J = 2.4 Hz) 9.32 (1H, d, J 
= 1.2 Hz); 13C NMR (100 MHz, CDCl3) δ 14.11, 22.67, 25.87, 28.60, 29.23, 29.33, 29.48, 
29.55, 29.61, 29.62, 31.90, 66.53, 163.98, 143.66, 144.45, 146.26, 147.55; MS +H+, 302.42. 
 
Tetradecylpyrazinoate:  
Waxy white solid; TLC hexane:ethyl acetate (4:1), rt 0.24; yield 100%; 1H NMR (400 
MHz,CDCl3) δ 0.81 (3H, t, J = 6.6 Hz), 1.14–1.32 (20H, m), 1.37 (2H, m), 1.76 (2H, m), 4.38 
(2H, t, J = 7.0 Hz) 8.67 (1H, dd, J = 2.4,1.2 Hz), 8.70(1H, d, J = 2.4 Hz), 9.25(1H, d, J = 1.2 
Hz); 13C NMR (100 MHz, CDCl3) δ 14.13, 22.69, 25.88, 28.61, 29.24, 29.36, 29.50, 29.56, 
29.64, 29.65, 29.66, 29.68, 31.92, 66.55, 164.00, 143.66, 144.45, 146.26, 147.55; MS +H+, 
330.47. 
 
Hexadecylpyrazinoate: 
Waxy white solid; TLC hexane:ethyl acetate (4:1), rt 0.25; yield 100%; 1H NMR (400 
MHz, CDCl3) δ 0.88 (3H, t, J = 6.6 Hz), 1.21–1.40 (24H, m), 1.45 (2H, m,), 1.83 (2H, m), 
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4.45 (2H, t, J = 6.8 Hz,) 8.75 (1H, dd, J = 2.4, 1.2 Hz), 8.77 (1H, d, J = 2.4 Hz), 9.32 (1H, d, J 
= 1.2 Hz); 13C NMR (100 MHz, CDCl3) δ 14.12, 22.69, 25.88, 28.60, 29.24, 29.36, 29.49, 
29.55, 29.56, 29.63, 29.66, 29.68, 29.69, 31.92, 33.00, 66.54, 163.98, 143.66, 144.45, 146.26, 
147.55; MS +H+, 358.52. 
 
4.1.2 Pyrazinamidase (PZase) assay and evaluation of in vitro activation of 
pyrazinamide and different analogues: 
In an attempt to evaluate the role of PncA gene mutation in mycobacterial PZA-
resistance, and in a trial to use the cell free PZase assay to assess the in vitro activation of 
PZA and its analogues into the active form POA, the following steps were done: 
 
4.1.2.1Expression and purification of PZase wild type and its mutants: 
Histidine tagged mycobacterial PZase (wild type) was expressed in E. coli BL21 in 
APS medium and purified with different steps of protein chromatography from Ni-NTA to Q-
Sepharose ion exchange chromatography and finally with sephadex-200 size exclusion 
chromatography  . The molecular weight and the purity of the purified enzyme were assessed 
in SDS-PAGE as shown in (Fig. 16).  
 
  
 
Fig (16): SDS-PAGE of Mycobacterium tuberculosis pyrazinamidase (wild type) after the 
different steps of protein purification: The molecular weight of the enzyme ranges between 
20-25 KDa.  
 
Similarly, 5 mutants of pyrazinamidase were purified using the affinity 
chromatography Ni-NTA. The amino acid substitution in the different mutants was 
Pyrazinamidase 
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characterized using the free online GENTLE software (table-9). The fractions collected from 
each mutant for the buffer exchange are shown in (Fig.17).  
 
Table (9): Types of mutation in pyrazinamidase gene from clinical PZA-resistant 
strains. 
Mutant number Type of mutation Amino acid change 
 
Mut-1 
 
MtPncA T515C 
 
Leu172Pro 
 
Mut- 2 
 
MtPncA A188G 
 
Asp63Gly 
 
Mut- 3 
 
MtPncA C475G 
 
Leu159Val 
 
Mut- 4 
 
MtPncA A287G 
 
Lys96Arg 
 
Mut- 5 
 
MtPncA T350C 
 
Leu117Pro 
 
                  
       
Fig (17): SDS-PAGE of 5 mutants of Mycobacterium tuberculosis pyrazinamidase. The 
figure shows the fractions collected after Ni-NTA chromatography for desalting and buffer 
exchange. M: protein marker.  
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4.1.2.2 Pyrazinamidase (PZase) assay: 
For quantification, standard curve was done first using different concentrations of 
POA alone with ammonium ferrous sulphate to correlate the absorbance at OD450 with the 
concentration of POA as shown in (Fig. 18). The cell free PZase assay was optimized to 
evaluate the PZA and its analogues as prodrugs that liberate the active form POA with the 
action of PncA.The characterization of the activity of the PZase and its mutants with PZA and 
its analogues was done by measuring the absorbance of the colored complex formed from the 
liberated POA and the ammonium ferrous sulphate at 450 nm. The rate of reactions was 
calculated (µM/min) and these rates were applied to Graphpad prism v5.0 for kinetic 
parameters calculation.  
 
 
 
Fig (18): pyrazinamidase assay in a 96 well plate: A, B& C show effect of increasing 
concentrations of PZA with the wild type of PncA. D, E& F show the control reactions with 
the product only POA without enzyme for the purpose of quantitation. 
 
 
4.1.2.2.1Evaluation of PZA as a substrate for mycobacterial PncA: 
The following figure and table are showing the kinetic of the wild type PncA with 
PZA. The calculated Km value with PZA was 1,271 mM. This high value shows a low 
specificity to PZA as a substrate. 
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Fig (19): Michaelis-Menten plot of the wild type of PncA: The rate of the reaction 
(µM/min) is plotted against the concentration of PZA (mM) 
 
Table (10): Kinetic parameters of the wild type of PncA with PZA. 
Michaelis-Menten  
Best-fit values  
Vmax 198,2
Km 1,271
Std. Error  
Vmax 2,636
Km 0,06183
95% Confidence Intervals  
Vmax 192.8 to 203.6
Km 1.146 to 1.397
Goodness of Fit  
Degrees of Freedom 34
R² 0,9944
Absolute Sum of Squares 739,9
 
4.1.2.2.2 Role of PncA mutation in clinical PZA-resistance: 
 For evaluation of the role of PncA mutations in the PZA-resistance, the rate of 
reactions carried by PncA mutants were evaluated and compared with the wild type as 
presented in (Fig.20). The Kcat was calculated for the wild type and the mutants. The Kcat is 
the turnover number which represents the number of times each enzyme site can convert the 
prodrug to its active form per unit time. Reactions with 1 mM of PZA were used for the 
calculation of the specific activity of the each enzyme (U/mg), where the unit (U) is the 
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amount of the enzyme that produces 1 micromole of POA per minute. The results were 
summarized in (table-11). 
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Fig (20): Comparison between the wild type of PncA and the 5 mutants using the 
pyrazinamidase assay: PZA was evaluated as a substrate at different concentrations which 
were plotted against the rates of reactions (µM/min). 5 times higher of the enzyme 
concentration was used with PncA-mut-1 and PncA-mut-4 due to their low activity. All 
mutants showed lower activity than the wild type and even complete inactivity as PncA-mut-4 
except PncA-mut-5 that showed higher activity. 
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Table (11): Kcat and the specific activity of different enzymes with PZA. 
     Kcat Specific activity (*U/mg) 
 
PncA-Wild type 45.04 ± 0.6    5.91 ± 0.12 
PncA-mut-1 7.2 ± 3.31    0.23 ± 0.08 
PncA-mut-2 16.3 ± 0.92    2.54 ± 0.6 
PncA-mut-3 18.17 ± 0.88    1.47 ± 0.15 
PncA-mut-4 NM    NM 
PncA-mut-5 725.1± 226    8.75 ± 0.45 
The data are presented as the mean ± standard deviation  
NM: Non-measurable. 
* One unit of pyrazinamidase was defined as the amount of enzyme required to produce 1 µmol of POA per 
minute. 
 
The results revealed that not all PncA mutants were inactive. PncA-mut-2 and PncA-
mut-3 retained some activity; however they transform PZA into POA at slower rates than that 
of the wild type. Even PncA-mut-5 had higher activity than the wild type. On the other hand 
PncA-mut-4 was completely inactive. 
 
4.1.2.2.3 Evaluation of the synthesized POA amides as prodrugs: 
 In order to evaluate the synthesized amides as prodrugs and their ability to liberate 
POA, the PncA reactions were carried with 1mM of PZA and different analogues to compare 
the rate of reaction with each substance. The three synthesized analogues were considered as 
very poor prodrugs since they almost could not be transformed to the active form with the 
PncA as shown in (Fig. 21). The synthesized analogues were also screened with the purified 
mutants and no activity was observed (the results are not shown). 
 
 
Fig (21): Screening of different analogues with pyrazinamidase assay: The three 
synthesized amides were considered as very poor prodrugs. 
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4.1.3 Pyrazinoic acid esters as an alternative to pyrazinamide, in vitro 
efficacy and toxicity: 
4.1.3.1 In vitro activity: 
Resazurin microtiter assay (REMA) was used to determine the minimal inhibitory 
cocentrations (MICs) of POA esters against the inherently PZA resistant strain, M. bovis 
BCG. The percentage of bacterial viability in comparison to untreated controls correlates with 
the reduction of resazurin to the red florescent resorufin. And the resulting change in color 
from blue to pink was detected and quantified by measuring the degree of fluorescence.  
 
      
      
 
Fig. (22): Resazurin microplate assay (REMA) 
with pzrayinamide (PZA), pyrazinoic acid 
(POA), and pyrazinoic acid esters. Serial 2-fold 
dilutions of each substance were prepared in a 
96-well plate, and their minimal inhibitory 
concentrations (MICs) against M. bovis BCG 
were evaluated in REMA. Results show the 
correlation of the substance concentration to 
fluorescence. The MIC for hexadecylpyrazinoate, 
tetradecylpyrazinoate, dodecylpyrazinoate, and 
POA were 25, 50, 50 and 250 µg/ml respectively. 
On the other hand, PZA did not inhibit the 
bacterial growth up to 250 µg/ml.   
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(Fig. 22) shows the inhibitory effect of POA esters in comparison to PZA and its 
active form pyrazinoic acid against M. bovis BCG.The MIC was defined as the concentration 
of the substance that inhibited more than 90% of bacterial growth. The percentage of growth 
inhibition was calculated as follows: 
 
Percentage of growth inhibition (%) = [1- (REMA florescence of a compound - REMA 
florescence of the sterile control) / (REMA florescence of the untreated control - REMA 
florescence of the sterile control)] * 100 
 
The MICs of hexadecylpyrazinoate, tetradecylpyrazinoate, dodecylpyrazinoate, and 
POA against M. bovis BCG were 25, 50, 50 and 250 µg/ml respectively. While, PZA did not 
inhibit the bacterial growth up to 250 µg/ml.  The MICs of the three esters against against M. 
tuberculosis H37Rv were evaluated in REMA, and the MIC was defined as the lowest 
concentration that prevented the transformation of the color from blue to pink (Table-12).  
 
4.1.3.2 In vitro toxicity profile: 
4.1.3.2.1 Effect on cell viability and selectivity index (SI): 
Cytotoxicity of the diﬀerent three POA esters was measured by using the 3-(4, 5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay on mouse 
connective tissue fibroblast L929 cells. The IC50 value, the dose inhibiting the 50% of cell 
viability, after 24 h and 5 days was calculated based on dose–response relationships. The ratio 
between IC50 and MIC against M. tuberculosis H37Rv was used to calculate the selectivity 
index (SI) of each compound as an estimate of the therapeutic window (Table-12).  
 
Table (12): Minimal inhibitory concentration (MIC), IC50, selectivity index (SI) of 
pyrazinoic acid esters:   
 
(MIC) against M. 
tuberculosis H37Rv 
(µg/ml) 
IC50  (µg/ml) in MTT 
with L929 cell line 
SI    (IC50/MIC) 
 5 days 1 day 5 days 1 day 
Hexadecylpyrazinoate 25 7 25 0.28 1 
Tetradecylpyrazinoate 25 20 >100 0.8 >4 
Dodecylpyrazinoate 50 20 >100 0.4 >2 
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The 3 POA esters were inhibiting the L929 cell proliferation as shown in the results of 
MTT assay after 5 days, however tetradecylpyrazinoate and dodecylpyrazinoate did not show 
acute toxic effect against the same cell line at all doses used in MTT assay after 1 day. The 
anti-proliferative effect of the three POA esters was further screened with different cell lines. 
The HUVEC cell line was tested as an example for primary cell lines, as well as the J774 a.1 
cell line to be comparable with the results of (Simões et al. 2009). (table-13) shows the 
calculated IC50 from the dose response curve in addition to the logp value which reflects the 
degree of the lipophilicity of the compounds. The results showed that the higher lipophilicity 
was associated with higher toxicity (lower IC50). In addition, the highest toxicity was noticed 
against the HUVEC cell line.  
 
Table (13): Lipophilicity and anti-proliferative effect of POA esters: 
 MIC (µM) Logp* IC50 (µM) 
   
HUVEC KB 3.1 Ptk2 J774 a1 HEPA 1.6 
Hexadecylpyrazinoate 70 5.85 7.8 26.6 22.4 55.9 42 
Tetradecylpyrazinoate 75.9 5.46 21.2 62.2 75.9 63.7 57.7 
Dodecylpyrazinoate 165.9 4.55 21.6 99.5 69.7 92.9 99.5 
* (Simões et al. 2009) 
 
 
4.1.3.2.2 Effect on cell morphology:  
Phenotypical changes in the nucleus and alpha tubulin and actin stress fibres were 
monitored in potoroo cells (PtK2) treated with  20 µg/ml of different compounds. And the 
endoplasmic reticulum was stained after the treatment with 10 and 20 µg/ml of each 
compound.   The 3 compounds at concentration 20 µg/ml induced stress of the endoplasmic 
reticulum that was revealed by the appearance of the stress vacuoles in comparison to the 
untreated cells. On the other hand cells showed normal appearance of the stress fibres and 
microtubules. 
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Fig (23): Immunoflorescent staining of alpha tubulin. A: Control of untreated cells, B: 
Hexadecylpyrazinoate, C: Tetradecylpyrazinoate, D: Dodecylpyrazinoate. PtK2 cells were 
incubated with 20 µg/ml of different compounds for 18 hours. In comparison with control 
cells, Treated cells show normal appearance of the microtubules. 
 
 
                   
 
Fig (24): Immunoflorescent staining of actin: A: Control of untreated cells, B: 
Hexadecylpyrazinoate, C: Tetradecylpyrazinoate, D: Dodecylpyrazinoate. PtK2 cells were 
incubated with 20 µg/ml of different compounds for 18 hours. In comparison with control 
cells, Treated cells show normal appearance of the actin stress fibres. 
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Fig(25)-a 
                  
 
Fig(25)-b 
             
 
Fig (25): Immunoflorescent staining of endoplasmic reticulum: A: Control of untreated 
cells, B: Hexadecylpyrazinoate, C: Tetradecylpyrazinoate, D: Dodecylpyrazinoate. PtK2 cells 
were incubated with 10µg/ml (a) and 20 µg/ml (b) of different compounds for 18 hours. In 
comparison with control cells, Treated cells at Conc. 20 µg/ml show vacuoles in the 
endoplasmic reticulum. While at Conc. 10 µg/ml, cells show normal morphological 
appearance. 
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4.1.3.2.3 Induction of apoptosis: 
Human macrophage cells U937 were treated with the IC90 of the POA esters (35µg/ml) 
for 12 hours. At this concentration hexadecylpyrazinoate, tetradecylpyrazinoate, 
dodecylpyrazinoate induced late apoptosis in 60.1, 85, and 98.4% of treated cells in 
comparison to 12.8 % in the untreated control. 
 
 
 
Figure (26). Flow cytometric analysis of apoptosis:  
U937  cells were treated with 35 µg/ml of the test compounds for 12 h, and stained with FITC 
Annexin V and propidium iodide (PI). Q4 contains the percentage of viable cells (stained 
neither with PI nor with FITC Annexin V); Q2 shows the percentage of late apoptotic cells 
(stained with both PI and FITC Annexin V), and Q3 the percentage of early apoptotic cells 
(stained with FITC Annexin V only). 
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4.1.3.2.4 Induction of reactive oxygen species: 
 As the induction of reactive oxygen species (ROS) is one of the common causes of the 
ER stress, the DCF assay was used to evaluate the induction of ROS by the three esters. The 
DCF assay was carried out after 1 hour of treating HEPA 1.6 cell line with different 
concentrations of the compounds and a control experiment with H2O2 was included. In 
comparison to the control experiment, the POA esters were found to have no role to induce 
the intracellular ROS levels. 
     
 
 
Fig (27): Evaluation of induction of reactive oxygen species (ROS) in HEPA 1.6 cell line 
after 1 hour treatment with different concentrations of pyrazinoic acid esters using the 
DCF assay: in comparison to the control experiment that was treated with H2O2, the 3 
pyrazinoic acid esters did not induce the intracellular ROS levels. 
 
 As revealed from the previous results, the three POA esters were found to have very 
narrow therapeutic window as revealed from their SI. They induced ER stress in Ptk2 cells at 
a concentration lower than their in vitro MICs. By testing the antiproliferative effect of the 
three compounds with different cell lines, it was noticed that their IC50 values were in reverse 
order of their lipophilicity. In addition the three esters had a lower IC50 against HUVEC cell 
line than other cell lines.  
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4.2 RNAP inhibitors: 
4.2.1 In vitro screening of different substances with RNAP assay. 
4.2.1.1 Validity of the assay: 
 
 As a preparatory step of the assay, different concentrations of ATP alone were 
measured with the Luciferin-Luciferase system (Fig. 28). Then the ability of ATP sulfurylase 
enzyme to utilize pyrophosphate (ppi) and to produce ATP was confirmed by measuring the 
liberated ATP from the reaction using the Luciferin-Luciferase system (Fig. 29).  
 
 
 
Fig. (28): Test of Luciferin-Luciferase system: The relative light unit (RLU) was measured 
with different concentrations of ATP (1 nM to 10 μM) with Luciferin-Luciferase System.  
 
 
 
 
Fig. (29): Pyrophosphate reaction to test the ability of ATP Sulfurylase to convert PPi 
into ATP: In the positive reaction, PPi was used as a substrate for ATP sulfurylase. ATP that 
produced from the reaction was then tested with Luciferin-Luciferase system and RLU values 
were measured. Rifampicin: rifampicin was added to the positive reaction, Negative: PPi was 
excluded and Zero: was the blank value. 
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Then the whole reaction was carried out starting by the reaction of RNAP followed by 
the sequential steps of the assay as described previously in the section of the materials and 
methods. In parallel the assay was performed with the presence of rifampicin (RIF) as an 
inhibitor of RNAP (Fig. 30). 
 
 
 
Fig (30): RNA polymerase reaction. Positive reaction contains all reactants necessary for 
RNAP Assay. Rifampicin contained rifampicin with the positive reaction, as an inhibitor of 
RNAP. Negative reaction did not have DNA necessary for the transcription of RNAP and 
Zero was the blank well. 
 
 
4.2.1.2 Screening potential drug candidates using the RNAP assay: 
 The inhibitory effect of different substances and LX cocktails was evaluated in the 
RNAP assay (Fig. 31). Almost all cocktails inhibited the RNAP in a dose related manner. On 
the other hand the OCI substances, intermediates in the synthesis of corallopyronin, showed 
no inhibitory effect. 
 
Fig. (31): Continued. 
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Fig. (31):  Screening of different substances in RNAP assay: RNAP assay was used to 
predict the inhibitory effect of different substances at different concentrations along with 
positive control that contained all constituents of the reaction, negative control in which 
RNAP was excluded and rifampicin (RIF) as a control of RNAP inhibition. The Y-axis 
represents the RLU and at the X-axis the substances are shown.  
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4.2.2 Evaluating the in vitro inhibitory profile and cellular toxicity of RNAP 
inhibitors (RNAPIs). 
4.2.2.1 Synergistic effect between RNAP inhibitors and ethambutol: 
The MICs for the individual RNAPI, corallopyronin, ripostatin and myxopyronin 
against M. tuberculosis H37Rv were evaluated in REMA as described above. Ethambutol is a 
commercially available anti-TB drug which functions through inhibiting the cell wall. And to 
evaluate the synergistic effect of the three RNAPI with ethambutol, the test was repeated 
using 7H9 medium containing sub-MIC of ethambutol to calculate the fractional inhibitory 
concentration (FIC). The synergism was considered when FIC is less than 1. The SI was 
calculated by dividing the IC50 obtained from the MTT assay over the in vitro MIC of each 
individual substance as shown in the following table. 
 
Table (14) Synergistic effect between the RNAP inhibitors and ethambutol: 
 MIC (µg/ml) against  
M. tuberculosis H37Rv 
 
 In vitro toxicity with 
L929 cell line 
 Individual 
substance 
 With medium 
containing 
ethambutol b 
 
 IC50 (µg/ml) a SI 
Myxopyronin 
 
6.25  3.125  >100 >16 
Corallopyronin 
 
12.5  12.5  25 2 
Ripostatin 
 
no inhibition up 
to 25 µg/ml 
 
 no inhibition up to 
25 µg/ml 
 >100  
Ethambutol 
 
1.6    >100 >62.5 
a MTT assay after 5 days. 
b Ethambutol at Conc. 0.3 µg/ml 
 
Myxopyronin did not inhibit L929 cell proliferation at all tested concentrations with SI 
more than 16. On the other hand corallopyronin exhibited low SI and ripostatin did not inhibit 
the growth of M. tuberculosis H37Rv up to concentration of 25 µg/ml.The results showed the 
synergistic effect between myxopyronin and ethambutol. The calculated FIC was less than 1.  
 
FIC = MIC ethambutol in combination/MIC ethambutol alone + MIC myxopyronin in 
combination/MIC myxopyronin alone = 0.3/1.6 + 3.125/6.25= 0.64         (FIC less than 1 
means synergism) 
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4.2.2.2Minimal inhibitory concentration of different combinations:  
REMA was used to determine the MICs of different combinations of myxopyronin 
and ethambutol against M. bovis BCG (Fig 32).  
 
     
     
      
 
 
Fig (32): Resazurin microplate assay 
(REMA) with RNAP inhibitors: 
Serial 2-fold dilutions of each cocktail 
were prepared in a 96-well plate, and 
their minimal inhibitory concentrations 
(MICs) were evaluated in REMA. The 
experiment includeded untreated 
controls treated only with the vehicle 
and sterile controls contain no bacteria. 
Results show the correlations between 
drug concentration and fluorescence. 
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4.2.2.3 Effect on cell viability and selectivity index: 
 As the different combinations inhibited the mycobacterium at low concentrations, they 
were further tested in MTT assay with L929 to determine the effect on cell viability and to 
calculate the selectivity index as shown in (table-15). 
 
Table (15) Minimal inhibitory concentration (MIC), IC50 and selectivity index (SI) of 
different cocktails: 
 MIC (µg/ml)a 
IC50 (µg/ml)
after 5 days b 
SI        
(cIC50/MIC) 
LX004 1.5 35 23.3 
 
LX018 
 
1.5 
 
>100 
 
> 66.7 
 
LX019 
 
1.5 
 
>100 
 
> 66.7 
 
LX021 
 
<0.8 
 
>100 
 
>125 
LX024 6.5 >100 > 15.4 
a MIC was calculated as the dose that inhibited more than 90 % of M. bovis BCG growth in REMA . b in MTT 
assy with L929 cell line. c IC50 after 5 days.  
 
 
The IC50 and MIC data, as described before, were used to calculate the SI as an 
estimate of the therapeutic window. All combinations did not inhibit cell proliferation at all 
tested concentrations except LX004. The combinations between myxopyronin and ethambutol 
inhibited the bacterial growth at lower concentrations at the same time they showed high SI 
even LX004 it has also wide safety margin.   
 
4.2.2.4 Effect on cell morphology:  
Phenotypical changes in the nucleus, endoplasmic reticulum (Fig. 33), microtubules 
(Fig. 34) and actin stress fibres (see appendix) were monitored in potoroo cells (PtK2) treated 
with  20 µg/ml of the individual substances.  
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Myxopyronin and ethambutol had no effect on the cell morphology. It was noticed that 
corallopyronin upon long storage it produced fragmentation of the nucleus. And as revealed 
from the staining of the microtubules, it induced abnormal mitotic spindles.  
A B
C D
E Fig (33): Immunoflorescent staining of 
endoplasmic reticulum: A: Control, B: 
Myxopyronin, C: Ethambutol, D: 
Corallopyronin, E: Corallopyronin after 
long storage. PtK2 cells were incubated 
with 20 µg/ml of different compounds for 
18 hours. In comparison with control cells, 
treated cells show also normal appearance 
of the endoplasmic reticulum and the 
nucleus except for corallopyronin after 
long storage which produced larger cells 
with fragmented nuclei. 
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Furthermore the diferent combinations between myxopyronin and ethambutol were 
also evaluated with regard their effect on cell morphology. All combinations did not produce 
any abnormality of the cellular structures, nuclus, endoplasmic reticulum, microtubules and 
stress fibres (see appendix). 
 
4.2.2.5 Effect of protein binding on in vitro MIC: 
 
 Binding to proteins in plasma is a very important factor that can influence the in vivo 
antimicrobial activity. For this reason, the MICs of Myxopyronin, ethambutol and their 
Fig (34): Immunoflorescent staining of 
microtubules: A: Control, B: 
Myxopyronin, C: Ethambutol, D: 
Corallopyronin, E: Corallopyronin after 
long storage. PtK2 cells were incubated 
with 20 µg/ml of different compounds for 
18 hours. In comparison with control cells, 
treated cells show also normal appearance 
of the microtubules and the nucleus except 
for corallopyronin after long storage which 
produced abnormal mitotic spindles and 
multinucleated cells.
A B
C D
E 
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combination in LX004 and LX018 against M. bovis BCG were investigated using resazurin 
assay in 100 % medium and with the presence of 50 % fetal bovine serum (FBS).  
 
Table (16): Effect of protein binding on in vitro MIC. 
  MIC in 100% medium 
 
 
With medium containing 50 % FBS 
  
Myxopyronin 
  
6.25 no inhibition up to 25 µg/ml 
Ethambutol 
  
2.5 2.5 
LX004 
  
 1.5 1.5 
LX018 
  
1.5 3.125 
  
 
 
 It was noticed that myxopyronin did not inhibit the growth of M. bovis BCG in the 
presence of 50% FBS with concentration 4 times higher than its MIC in 100 % medium. On 
the other hand, the MICs of the LX004, LX018 and ethambutol were not affected by the 
addition of the FBS. These two combinations retained FIC below than 1 even with the 
presence of FBS. 
 
 In between the three RNAPIs, myxopyronin, ripostatin and corallopyronin, we found 
that myxopyromin seems to be very attractive for further testing. Beside that it showed a 
satisfactory SI, it exhibited synergism with the cell wall inhibitor, ethambutol. The results 
showed that the high binding of myxopyronin to proteins might be compensated with this 
synergistic effect in vitro.   
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4.3 Random library of compounds: 
4.3.1 In vitro screening of a random library of compounds: 
4.3.1.1 Primary screening: Evaluating the in vitro antituberculous activity:   
 A library of about 480 compounds was screened against M. tuberculosis H37Rv using 
REMA. In between the 480 compounds, 5 compounds had low or submicromolar MIC 
(Table-16).  
 
4.3.1.2 Secondry screening: Evaluating the in vitro toxicity profile against 
mammalian cells. 
Subsequently, the in vitro cytotoxicity and SI of the 5 compounds were assessed using 
the MTT assay with L929 cell line after 1 and 5 days. The MIC, IC50 and the SI of the 5 
compounds are listed in (Table-16).  
 
4.3.1.2.1 Effect on cell viability and selectivity index:  
In between the 5 compounds the, LX077 and LX079 had the most promising results. 
When the SI was calculated by the IC50 obtained after 5 days incubation with the substances, 
their SI were exceeding 10. And their SI when calculated from IC50 from the acute toxic effect 
experiment, their SI were 30.6 and 65.3 respectively. 
 
Table (16) Minimal inhibitory concentration (MIC), IC50 and selectivity index (SI) of the 
selected compounds: 
 
(MIC) against M. 
tuberculosis H37Rv(µg/ml) 
IC50  (µg/ml) in MTT with 
L929 cell line 
SI   
(IC50/MIC) 
 5 days 1 day 5 days 1 day 
      
LX076 0.32 0.6 6.8 1.88 21.3 
LX077 0.15 2 9.8 13.3 65.3 
LX078 0.07 0.07 7.2 1 103 
LX079 0.18 2.2 5.5 12.2 30.6 
LX080 0.19 0.1 1.29 0.53 6.8 
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4.3.1.2.2 Effect on cell morphology: 
Ptk2 cell lines were treated with 5µg/ml of different compounds then the 
immunoflorecent staining for the ER was carried out. The effect of the different compounds is 
shown in (Fig. 35). Cells that were treated with LX079 showed normal appearance. LX076 
and LX077 produced the appearance of the ER stress. At the same concentration, the other 
two compounds induced death of the most of cells. 
 
  
 
  
 
Fig (35): Immunoflorescent staining of endoplasmic reticulum: A: Control of untreated 
cells, B: LX079, C: LX077, D: LX076. PtK2 cells were incubated with 5 µg/ml of different 
compounds for 18 hours. In comparison with control cells, Treated cells show normal 
appearance after treatment with LX079, while after treatment with LX077 and LX076 cells 
are showing the appearance of ER stress. At the same concentration the other 2 compounds, 
the most of cells were died (no picture). 
  
Thus, based on the results of in vitro studies, compound LX079 had the most favorable 
safety profile. And it was advanced into in vivo experiments. 
4.3.2 Acute oral toxicity: 
 The acute oral toxicity of LX079 was evaluated in C57/BL6 mice after single oral 
dose. The animals were observed for 14 days after dosing. The characteristic observed signs 
and the survival of animals are summarized in table (17).  
A 
C D
B
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Table (17): Characteristic signs and survival of C57/BL6 mice at different doses of 
LX079. 
Dose (mg/kg) Time post dosing Characteristic signs 
62.5 
30 - 240 min Normal appearance and behavior as healthy 
mice 
240 min Appearance of slight tremors 
240 min-24 hr. Apparent recovery 
Following 14 days 
Normal appearance and behavior as healthy 
mice 
125 
30 - 240 min 
Three mice showed respiratory distress, tremors, 
lethargy and sleep. While the other 2 mice 
showed normal appearance and behavior. 
240 min 
One of healthy mice started to show bad skin 
conditions 
240 min - 24 hr. 
2 mice with tremors and respiratory distress start 
to convulse, and they were sacrificed to avoid 
more suffering. The others start to recover 
Following 14 days 
The remaining surviving 3 mice showed normal 
appearance and behavior as healthy mice. 
250 
30 - 180 min 
3 mice showed respiratory distress, tremors and 
sleep. 
180 - 240 min 
The other 2 animals started to show tremors and 
sleep 
240 min 
One mouse showed convulsion and it was 
humanely killed to avoid more suffering.  
240 min -24 hr. Recovery of the remaining 4 animals 
Following 14 days 
The remaining surviving 4 mice showed normal 
appearance and behavior as healthy mice. 
 
In the acute oral toxicity studies, 100 % survival was recorded in the animals that 
received 62.5 mg/kg, However, the mice showed slight tremors after 4 hours of the treatment 
which recovered during the first 24 hours  . The percentages of cumulative deaths between the 
animals received 125 and 250 mg/kg were 22 and 42.85 % respectively (table-18).  The 
animals that received 125 and 250 mg/kg presented with respiratory distress and neurological 
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signs like tremors and sleep. These toxic manifestations recovered slowly during the first 24 
hours and then the surviving animals exhibited normal appearance and behavior like the 
control groups. While the 3 animals that were decided to be humanely killed started to 
convulse.   There was no significant change in the body weight between the treated and the 
control groups; however the animals that received 125 mg/kg showed weight loss after the 
first week which was increased again normally by the end of the experiment (table-19).  
Macroscopic examinations did not show any changes in the appearance of the organs of the 
treated animals compared with the control group. 
 
Table (18): The acute oral toxicity of LX079 in C57/BL6 mice. 
Group  No. of 
Mice 
Dose 
(mg/kg) 
No. of dead 
mice 
% Cumulative of 
dead mice* 
 
Macroscopic examination 
(liver, lungs, kidneys, 
spleen)  
 
1 5 control 0 0 Normal 
2 5 62.5 0 0 Normal 
3 5 125 2 22 Normal 
4 5 250 1 42.85 Normal 
*  using Reed–Muench method. 
 
 
Table (19): Effect of administering different doses of LX079 on body weight of C57/BL6 
mice over a period of two weeks. 
Dose (mg/kg) Day 0 Day 7 Day 14 
 
Control 19.42 ± 0.53 19.62 ± 0.33 19.9 ± 0.7 
62,5 19.62 ± 0.68 20 ± 0.8 20.3± 0.37 
125 19.13 ± 0.49 18.87 ± 0.74 20.2 ± 0.85 
250 18.88 ± 0.15 19.15 ± 0.31 19.65 ± 0.47 
The results are presented as the mean ± standard deviation. 
 
The microscopic examination of the organs illustrated in (Fig. 36) revealed no 
differences between the control and test groups. All the organs from the treated mice did not 
show any change in cell structure or any abnormal effects when visualized under the light 
microscope. The appearance and the coordination of cells in organs from treated groups are 
more or less similar with the control group. 
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Fig. (36): Histological examination of the isolated mice organs in the acute oral toxicity 
experiments: left: the control group, right: the group dosed with 250 mg/kg. A: lung, B: liver, 
C: kidney, D: spleen. The histological features in organs from treated groups are more or less 
similar with the control group. 
A A
BB 
C C
DD 
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4.3.3 In vivo pharmacokinetics: 
The in vivo pharmacokinetics (PK) of LX079 was evaluated in C57/BL6 mice after 
oral and IV administration. The plasma concentration-time profile after 12.5 mg/kg single IV 
dosing is shown in (Fig. 37) and the related PK parameters are listed in (table-20). The plasma 
concentration-time profiles of LX079 after 12.5 and 25 mg/kg single oral administration are 
shown in (Fig. 39). (Table -21) shows the oral bioavailability with each dose. 
Time (h)
0 2 4 6
0.0
0.2
0.4
0.6
0.8
 
Fig. (37): Mean plasma concentration–time profile of LX079 in mice plasma following 
intravenous administration at 12.5 mg/kg. The red line represents the in vitro MIC of 
LX079 against M. tuberculosis H37Rv. 
 
 
Table (20)Pharmacokinetic parameters of LX079 in mice plasma following intravenous 
administration at 12.5 mg/kg. 
C0 (µg/ml) 0.66 ± 0.07 
 
AUC (h.µg.ml-1) 0.53 ± 0.03 
 
t1/2 (h) 0.43 ± 0.27 
 
K 1.79 ± 0.44 
 
CL (l . h-1 . kg-1) 23.64 ± 1.22 
 
Values are represented as mean ± SD. n = 3 at each time point. AUC: Area under the 24 hour plasma 
concentration-time curve. t1/2: Half-life. K: Elimination rate constant. CL: clearance.  
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Fig. (38): Mean plasma concentration–time profiles of LX079 in mice plasma following 
oral administration at 12.5 and 25 mg/kg. The red line represents the in vitro MIC of 
LX079 against M. tuberculosis H37Rv. 
 
 
Table (21): Pharmacokinetic parameters of LX079 in mice plasma following oral 
administration at 12.5 and 25 mg/kg. 
Dose (mg/kg) AUC (h.µg.ml-1) F (%) 
 
12.5 0.15 ± 0.02 27.58 ± 2.46 
 
25 0.35 ± 0.07 32.66 ± 7.72 
 
Values are represented as mean ± SD. n = 3 at each time point. AUC: Area under the 24 hour plasma 
concentration-time curve. F: Bioavailability. 
 
 After IV administration of LX079 intravenously, it exhibited t1/2 of 0.43 ± 0.27 and the 
peak plasma concentration was 0.66 ± 0.07. The time in which the plasma concentration was 
exceeding the in vitro MIC (T > MIC) was less than 1 hour. After oral administration at 12.5 
and 25 mg/kg the oral bioavailability was estimated 27.58 ± 2.46 and 32.66 ± 7.72 
respectively and the plasma levels did not reach the level of the in vitro MIC. 
 
4.3.4 In vitro pharmacokinetic studies: 
The stability of the compound with hepatic microsomes was investigated. In vitro 
incubation of LX079 with pooled mice hepatic microsomes resulted in in vitro t1/2 of 5.94 ± 
2.36 (Fig. 40). The in vitro clearance (CLint, inc) was calculated with the consideration of the 
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binding to microsomes. The hepatic intrinsic clearance (CLint) was estimated by scaling up the 
in vitro t1/2 (Table-22). 
 
Fig. (40): In vitro metabolism by mouse liver microsomes of LX079: The substance was 
incubated with pooled mice hepatic microsomes in the presence of NADPH as a cofactor. The 
reaction was quenched at different time points. The percent of the parent substance was 
calculated in comparison to the concentration of the substance at time point 0. 
 
 
Table (22): Metabolic stability parameters of LX079 in mice microsomes. 
t1/2 (min) 5.937 ± 2.36 
 
CLint, inc (ml/min/mg protein) 2.82 ± 1.12 
 
CLint (ml/min/SMW) 221.81 ± 88.23 
 
Stability (%) 23.14 ± 2.01 
 
SMW: Standard mouse weight. 
 
 
The extent of binding to plasma proteins was not calculated. As after quantification of 
the parent substance in both sides after 4 hours of dialysis, it was much lower than the starting 
concentration. This finding may account to instability in mice plasma. 
 
 
 
 
85 
 
5. Discussion: 
As was introduced, this work is an approach to characterize potential drug candidates 
against mycobacterium tuberculosis (M.tb) in order to provide scientific database about the 
efficacy/safety profile for further drug development steps.  
 
The drug research pathway is a very complicated multidisciplinary process. The 
success for one drug molecule to reach the patient approximately needs 12-15 years and costs 
US$ 400–650 million (Panchagnula & Thomas, 2000). The spread of resistance to anti-TB 
drugs represents a big challenge in front of physicians and pharmacologists. The main aim of 
new anti-TB drug discovery process is to find compounds that exhibit higher efficacy, could 
be administrated less frequent, have the ability to shorten the period of treatment and showing 
less drug related toxicity and drug interactions (Sarkar & Suresh, 2011). 
 
5.1 Pyrazinamide: 
5.1.1 PncA mutations and clinical pyrazinamide resistance: 
Pyrazinamide (PZA), one of the first line anti-TB drugs, played a key role in 
shortening the duration of therapy from 12 to 6 month due to its ability to kill persisting 
bacilli in the acidic environment. The mycobacterial pyrazinamidase (PZase) encoded by 
PncA is involved in the activation of the prodrug PZA into its active form pyrazinoic acid 
POA; however the mechanism by which POA kills the mycobacterium is still not completely 
understood whether it is due to general acidification of the cytoplasm or via targeting specific 
cellular target. Numerous mutations in PncA gene were identified and thought to be the main 
cause for mycobacterial PZA-resistance (Scorpio & Zhang, 1996) (Zhang et al., 2008) (Barco 
et al., 2006) (Portugal et al., 2004). These mutations are located along the whole gene as well 
as in the upstreamed putative regulatory region with new mutations are continuously reported 
in new studies. The cause of this marked diversity of mutations is not clear; however it is 
believed that PncA gene is located in a hotspot for mutation in the mycobacterial genome 
(Scorpio & Zhang, 1996). 
 
 In order to assess the molecular mechanism of mycobacterial PZA-resistance, PncA 
enzymes from the native type M. tuberculosis H37Rv and from 5 PZA-resistant clinical 
strains were expressed, purified and their activity were characterized using the cell free PZase 
assay. The Wayne’s method that was modified by (Bhuju, 2009) was optimized and used for 
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screening of the activity of different enzymes as well as to screen different analogues as 
prodrugs in comparison to PZA. The kinetics of the native type PncA with PZA was evaluated 
with calculated Km 1.271 mM indicating the low specificity of PZA as a substrate for PncA. 
This can explain why the PZA is more active against non-replicating or old dormant bacilli 
inside macrophage. In these populations of bacilli the passive uptake of HPOA is not affected 
while the active efflux of POA- is down regulated, which leads to trapping of the POA inside 
the bacteria regardless the slow rate of its production. This low specificity also can elucidate 
the lack of PZA to early bactericidal activity which was described in some previous studies 
(Gumbo et al., 2009).  
  
 In between the 5 mutants that were studied, only one mutant (mut-4 Lys96Arg) was 
found to be completely inactive. (Zhang et al., 2008) in their study of mutants generated by 
site directed mutagenesis showed that Asp8, Lys96 and Cys138 are key residues in the 
catalysis of PZA. In our study, in between the 5 clinical PZA-resistant mutants, the only 
mutant that showed complete loss of PZase activity had substitution at Lys96 amino acid 
which is going with the results of Zhang and his colleagues. 
 
On the other hand, 3 mutants (mut-1 Leu172Pro), (mut-2 Asp63Gly) and (mut-3 
Leu159Val)  were still retaining different extent of activity with turnover number Kcat 7.2 , 
16.3, 18,17 respectively in comparison to 45.05 for the wild type. Partial activity of the 
enzyme slows the rate by which the PZA liberate the bactericidal form POA. The rate of 
conversion would consequently have an important role in determining the PZA susceptibility. 
As well as, we revealed one mutant (mut-5 Leu117Pro) with higher PZase activity than the 
native type with Kcat 725.1 which means 15 times higher than the wild type. The presence of 
clinical mycobacterial PZA-resistant strains that retain PZase activity in spite of mutations in 
PncA gene has been reported before (Mestdagh et al., 1999) (Lemaitre et al., 2001). Other 
mechanisms of PZA resistance related to high active efflux for POA and lack of uptake for 
PZA were studied in naturally PZA-resistant, PZase positive strains as M.smegmatis and 
M.avium (Sun & Zhang, 1999) (Sun et al., 1997) (Zhang et al., 1999) (Raynaud et al., 1999). 
Such mechanisms might explain the PZA resistance observed with mut-5 which showed much 
higher PZase activity than the native type. In the future using such strains for whole genome 
sequencing, evaluation of the effect of efflux inhibitors as reserpin on retaining the sensitivity 
to PZA and measuring the POA intracellular   should be valuable in determining the exact 
cause of resistance and might help to define new drug target of PZA 
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5.1.2 Evaluation of pyrazinoic acid amides as prodrugs using the cell free 
pyrazinamidase assay: 
 In parallel three pyrazinamides were synthesized -hexadecylpyrazinamide, 
tetradecylpyrazinamide and dodecylpyrazinamide- to be evaluated as prodrugs in the PZase 
assay. In this study the cell free PZase assay was used as a tool to evaluate the ability of 
different pyrazinamides to liberate POA.   The three amides could not be easily activated to 
release POA at an appropriate rate. (Simões et al., 2009) by using HPLC showed the very low 
activation of these 3 amide by M. smegmatis homogenate.  
 
5.1.3 POA esters as an alternative for pyrazinamide:  
 The mechanism of resistance to PZA is still a mystery to science despite of the 
continuous research in this field. PZA has a crucial role in achieving sterilization due to its 
high activity against slowly growing bacilli inside macrophage and semidormant population 
within the solid caseous lesions. The susceptibility of PZA-resistant strains to POA 
encouraged the field of molecular modification certainly the prodrug approach to find 
alternatives for PZA (Dutra et al., 2012). Lipophilic POA esters as an alternative 
antimycobacterial agent might have two specific advantages: 1. they would be easy to 
penetrate the lipophilic cell wall of mycobacterium, and 2. they can skirt the mutation in PncA 
through their activation with non-specific estrases instead of PZase. The main hindrance 
facing such compounds is their instability in   Serum. (Simões et al., 2009) showed that the 
stability in serum can be improved with compounds which have longer side chain. From this 
point, we synthesized the three esters mentioned by (Simões et al., 2009) in order to evaluate 
their efficacy and safety profiles as potential drug candidates. The rationale for using M. bovis 
BCG stems from the fact that M. bovis BCG is a naturally PZA-resistant strain, to evaluate the 
effectiveness of these compounds against PZA-resistant mycobacterium in comparison to 
PZA and POA.  
 
 Hexadecylpyrazinoate, tetradecylpyrazinoate and dodecylpyrazinoate were found to 
have minimal inhibitory concentration (MIC) against both M. bovis BCG and M. tuberculosis 
H37Rv 5-10 times lower than the POA, the active counterpart of PZA. In the present study 
and on contrary to the results of (Simões et al., 2009), the three esters inhibited the 
mammalian cell proliferation when tested with different cell lines indicating relatively poor 
selectivity. Furthermore, treating Ptk2 cell line with the three esters at concentration 20 µg/ml 
revealed induction of the endoplasmic reticulum (ER) stress. The present study showed that 
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substances with higher lipophilicity had the higher cytotoxicity. The order of the IC50 
concentrations for the three esters was the reverse order of the lipophilicity. The comparative 
IC50 values were dodecylpyrazinoate > tetradecylpyrazinoate > hexadecylpyrazinoate. In 
addition the three compounds showed more cellular toxicity when they were evaluated with 
HUVEC cells as a primary cell line. 
 
In the double-staining assay by flow cytometry, the percentage of annexin- and PI-
positive late apoptotic cells was markedly increased upon cell treatment with the three esters 
at a concentration of 35µg/ml for 12 hours. However there is no comparative increase of the 
annexin-positive and PI negative early apoptotic cells over the control untreated cells. Cells 
that stain positive for FITC Annexin V and negative for PI are going through apoptosis. While 
cells that stain positive for both FITC Annexin V and PI are either in the end stage of 
apoptosis, or are undergoing necrosis. So the increase of the anexin- and PI-positive cells 
alone reveals less information about the process by which the cells die. 
 
Hepatotoxicity is one of the main side effects of PZA. The exact mechanism by which 
PZA induces the hepatic injury is still unclear. However, recent studies revealed the strong 
correlation between hepatic toxicity induced by anti-tuberculous treatment and oxidative 
stress in experimental animals (Thattakudian Sheik Uduman et al., 2011) (Tostmann et al., 
2008). In addition, oxidative stress is implicated in a diversity of drug induced toxicities. ER 
stress and induction of intracellular reactive oxygen species (ROS) are also strongly 
correlated events. ROS liberate during normal oxygen-using cellular metabolic processes and 
have roles in cell signaling and homeostasis. The ER is considered as a unique oxidizing 
environment for protein folding and disulfide bond formation. But excessive ROS 
accumulation can happen as a consequence of different stressors as the exposure to toxicants 
with subsequent local oxidative stress and stimulation of adaptive responses. In another way 
accumulation of misfolded proteins in the lumen of the ER induces ROS production that 
function as a second messenger activating the unfolded protein response (UPR) and apoptosis 
in case of sustained stress and unresolved misfolded proteins (Malhotra et al., 2008) (Deavall 
et al., 2012). Our results revealed the ability of the three POA esters to produce ER stress. So 
we evaluated the ability of these compounds to induce intracellular ROS using the DCF assay. 
In our results, the three POA esters had no role in the induction of intracellular ROS.  
 
89 
 
 The results of the present study demonstrate that POA esters with high lipophilicity 
were more toxic. The degree of reduction of cell viability was correlated with the lipophilicity 
which was presented as octanol/water partition coefficient (logp). We cannot deny that the 
molecular modification strategy is a promising tool in the drug discovery pathway. We can 
obviously recognize this from the current anti tuberculosis discovery pipeline in which the 
molecular modification had played an important role (Dutra et al., 2012).  However, the 
physiochemical properties of the resulting compounds needs to be considered as the change of 
the physiochemical properties of the compound will lead to change of the efficacy/toxicity 
profile that can lead to rapid attrition from the discovery pathway. Lipophilicity is an 
important property which enhances the affinity of the compound to bind with its lipophilic 
binding site. On the other hand enhanced lipophilicity will increase the non specific binding in 
the lipophilic environments as in the cell membrane with subsequent lack of selectivity and 
increased nonspecific toxicity (wang et al., 2003) (Leeson & Springthorpe, 2007). 
 
5.2 RNA polymerase inhibitors: 
Bacterial DNA-dependent RNA polymerase (RNAP) is an attractive drug target. The 
inactivation of this crucial enzyme would lead to cell death. In addition, bacterial RNAP does 
not share extensive sequence homology with eukaryotic RNAP (Bai et al., 2011). Generally, 
RNAP assay as a target based screening tool has the advantage of speeding the role of 
medicinal chemistry to modify the compounds in a way that continue to hit the desired target 
(Nuermberger et al., 2010). The RNAP assay that was developed by (Bhuju, 2009) has many 
advantages over the previously used RNAP assays. In this study, we used this assay with few 
modifications. Increasing the concentration of adenosine 5´ phosphosulfate (APS) and the 
time of the reaction catalyzed by the ATP sulfurylase enzyme and using the half area plates 
improved the reproducibility of the assay. Furthermore, the assay was used to predict the 
inhibitory effect of different combinations that contain RNAP inhibitors (RNAPIs). The 
results showed the inhibitory effect of different combinations on the RNAP in a dose related 
manner. The OCI substances are intermediates in the synthesis of corallopyronin. They were 
evaluated in the RNAP assay but they did not show any inhibitory effect. 
 
The absence of cross resistance between rifampicin (RIF) and the RNAPIs 
myxopyronin, corallopyronin and ripostatin make them very attractive molecules for the 
researchers in the field of new anti-TB drug discovery. We evaluated the in vitro 
antimycobacterial activity of the three compounds. The results revealed MIC of myxopyronin 
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and corallopyronin 6.25 and 12.5 µg/ml respectively, while ripostatin did not inhibit the 
bacterial growth up to concentration of 25 µg/ml. with the evaluation of the in vitro toxicity 
profile, corallopyronin showed low selectivity with selectivity index (SI) of 2. In addition, 
corallopyronin seems to be upon long storage transforms into highly toxic compound which 
affects the mammalian cell division through its toxic effect on the cellular microtubules 
leading to large multinucleated cells. 
 
With our results and with the results of (Mariner et al., 2011) who showed the easy 
development of corallopyronin resistance, we concluded that corallopyronin is not a 
promising antimycobacterial drug candidate. 
 
On the other hand, myxopyronin showed higher safety margin with SI greater than 16. 
Furthermore, myxopyronin showed synergistic effect with the commercially available 
antimycobacterial agent, ethambutol with FIC of 0.64. The rationale to investigate the 
synergism between the three RNAPIs and ethambutol comes from the fact that the 
susceptibility of M. tb to antibiotics is usually increased by the cell wall inhibitors. In our 
results, corallopyronin and ripostatin did not show synergism with ethambutol. 
 
Additionally, the all combinations between myxopyronin and ethambutol showed high 
antibacterial activity against M. bovis BCG with wide safety margin with no detectable effect 
on the cellular structures with immunocytochemistry (ICC) staining even with concentrations 
much higher than their MIC.  
 
Furthermore, by testing the in vitro MIC with the presence of 50 % fetal bovine serum 
(FBS), we found that myxopyronin lost its anti-TB activity even with concentrations 4 times 
higher than its MIC in 100 % medium indicating high binding to proteins. At the same time 
the combination between myxopyronin and ethambutol retained its low MIC with the 
presence of 50 % FBS. Depending on these results, the combination between myxopyronin 
and ethambutol is likely to be promising. Ethambutol is a cell wall inhibitor and its in vitro 
MIC was not affected by the addition of the FBS. This is matching with the results of (Lee et 
al., 1977) who showed that the extent of ethambutol binding to plasma proteins ranges 
between 20 and 30 %. Ethambutol through its action on the cell wall of the microbe may 
facilitate the entrance of the myxopyronin to inhibit the RNAP even with low concentration of 
the free fraction. 
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Myxopyronin was discovered more than 30 years ago. It was considered very 
attractive RNAPI due to the absence of cross-resistance between RIF and myxopyronin. The 
physiochemical properties of myxopyronin and its high binding to plasma proteins were 
restrictive factors to enter the subsequent stages of the discovery pathway. The extent of 
binding to plasma proteins can affect the antimicrobial activity of an antibiotic through 
different aspects. The bound antibiotic is in a temporary inactive state that cannot hit the 
microbe. Additionally,   high binding to plasma proteins usually limits the distribution of the 
antibiotic. The percentage of binding determines the rate by which the antibiotic diffuses to 
the extravascular compartment. And for highly bound drugs, the half life (t1/2) will determine 
if the drug can reach a satisfactory level in tissues or not (Rolinson, 1980). In the future, 
studying the pharmacokinetic (PK) profiles of myxopyronin in vivo and in vitro, evaluating 
the PK/PD parameters of myxopyronin together with ethambutol in different combinations, 
and the extent of their binding to proteins can help to select a suitable dose regimen to be 
further tested in infection animal models.        
 
5.3 Random library of compounds: 
5.3.1 In vitro screening: 
In comparison to target-based screening approaches to discover new anti-TB agents, 
the whole cell based screening approaches showed more promising outcomes. All anti-TB 
drug candidates that are currently in clinical trials were first discovered by their antibacterial 
activity in whole-cell based screens. In the whole cell-based screening, the resazurin 
microtiter assay (REMA) was applied where ≈480 compounds were tested against M.tb. 
Based on this screening, 5 molecules inhibited the growth with micromolar concentrations 
were selected to evaluate their toxicity profile. Hits should be evaluated in terms of its 
cytotoxicity on mammalian cells before taking them ahead into the subsequent stages of the 
discovery chain. Here, cytotoxicity of the 5 hits was estimated against L929 cell line by using 
standard cell proliferation assay. It was observed that there was no significant effect on 
proliferation of L929 cell line at a concentration 10 times higher than MIC levels of 2 hits. 
After ICC staining, the LX079 was the only hit that showed no morphological changes of the 
treated cells at a concentration 25 times higher than the MIC. This data indicated that LX079 
could be selected for further drug development. 
 
In antimicrobial in vitro models, the activity of compounds is usually expressed by 
numeric values (IC50, IC90, MIC, etc.). The optimal value for whole-cell screening is 1 µg/ml. 
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Generally, MIC less than 2 µg/mL with a SI more than10 is assumed to be interesting for 
further development (Sánchez & Kouznetsov, 2010).  
 
5.3.2 Acute oral toxicity: 
To enable further studies, the acute toxicity of the new compound was evaluated in 
mice. Acute toxicity studies in animals are usually essential to give preliminary indications on 
the range of doses that could be toxic to the animal. Acute toxicity is the toxicity developed 
by a compound when it is administered in one or more doses through a period not more than 
24 hours. And according to the OECD guidelines for testing toxicity of chemicals (425-
OECD guideline for testing of chemicals), animals should be followed for 14 days after 
dosing to reveal any delayed toxicity. This kind of experiments should be designed to obtain 
the highest amount of information from the lowest number of animals. Using large number of 
animals to calculate lethality parameters is not recommended any more (Federal Register of 
October 11, 1988, 53 FR 39650).  The information obtained from these studies together with 
the PK characteristics of a new compound   is valuable in choosing doses for repeat-dose 
studies. Acute toxicity studies can provide clues about the possible target organs of toxicity 
and might help in selecting starting doses for phase 1 human studies. Furthermore, acute oral 
toxicity studies can provide relevant information about the acute overdosing in humans.  
 
By calculating the cumulative percentage of death between the mice, the LD50 was 
estimated to be more than 250 mg/kg. However; animals that were dosed with 62.5 mg/kg 
manifested with slight tremors and with higher doses animals showed respiratory distress with 
neurological manifestations as tremors, lethargy and sleep. All manifestations in the surviving 
animals disappeared during the first 24 hours and no delayed toxic signs were predicted 
during the whole period of the experiment. As well as no significant histopathological or body 
weight changes were detected in all tested groups. 
 
5.3.3 Pharmacokinetic/Pharmacodynamic (PK/PD) evaluation: 
The integration between the in vitro efficacy expressed in MIC and the in vivo 
pharmacokinetics (PK) is very valuable in expecting the antimicrobial outcome. In addition, it 
has a very important role in optimizing the dosage regimens. The results of some previous 
studies demonstrated that the magnitude of the PK/PD parameters needed for the 
antimicrobial efficacy is quite similar in both human and animal model infection (Craig, 
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1998). For this reason the PK profiles for the LX079 were evaluated in mice following oral 
and IV administration. 
 
The in vivo PK profile as well as the in vitro stability with hepatic microsomal 
enzymes was evaluated. The LX079 exhibited unfavorable in vivo PK pattern with short t1/2 of 
0.43 h ± 0.27 with very rapid clearance of 23.64 l . h-1 . kg-1 ± 1.22. The time in which the 
plasma conc. of LX079 was higher than the in vitro MIC (T > MIC) was less than 1 hour after 
IV bolus administration of the substance at 12.5 mg/kg. Following the oral administration at 
12.5 and 25 mg/kg, the oral bioavailability was 27.583 ± 2.457 and 32.662 ± 7.715 
respectively and the whole concentration-time curves were below the level of the in vitro 
MIC.  
 
These findings are correlated with the low stability (23.14 % ± 2.01) of the compound 
when incubated with mice hepatic microsomal enzymes. LX079 exhibited very short in vitro 
t1/2 of 5.94 ± 2.36 min with very high hepatic intrinsic clearance of 221.81± 88.23 (ml . min-1/ 
standard mouse weight) when scaled from the in vitro data. Extensive first pass effect of the 
liver eventually leads to poor bioavailability and short t1/2. 
 
We did not calculate the binding of the substance to the plasma proteins. As we found 
that the concentration of the substance in the both chambers after 4 hours of dialysis is much 
lower than the starting concentration. This finding may indicate also instability of the 
compound in mice plasma. This observation with the very high calculated hepatic intrinsic 
clearance value may account to the low initial concentrations in mice plasma following 
administration. 
 
In the aim to achieve better stability using the molecular modification, 20 analogues of 
LX079 will be further tested for lead optimization.  
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6. Summary: 
 Pyrazinamide (PZA) is an effective sterilizing anti-TB agent. Its mechanism of action 
is still controversial. PncA mutations are responsible for PZA-resistance in the most of 
resistant strains. 
 
 In order to characterize the role of PncA mutations in PZA-resistance, the kinetics of 
the pyrazinamidase (PZase) -wild type and 5 mutants from 5 resistant strains- were 
evaluated using the cell free PZase assay. 
 
 We showed low specificity of PZA as a substrate for the wild type PZase. This can 
explain its higher activity against old dormant or non-replicating bacilli. 
 
 In between the studied 5 mutants, only one mutant was found to be completely 
inactive. Three mutants were retaining different extent of activity with slower rate of 
conversion of PZA into pyrazinoic acid (POA) than the wild type. This indicates that 
the rate of conversion is an important factor in determining the susceptibility to PZA. 
 
 One mutant was found to have higher activity than the wild type suggesting other 
mechanism of PZA-resistance. 
 
 The molecular modification strategy would play an important role in achieving new 
anti-TB agents. And due to the susceptibility of the most PZA-resistant strains to 
POA, we synthesized lipophilic POA analogues -3 amides and 3 esters- in order to 
evaluate their efficacy/safety profiles. 
 
 The POA amides were evaluated as prodrugs using the cell free PZase assay. They 
were considered very poor prodrugs as they could not liberate POA at an appropriate 
rate.  
 
 The POA esters could be considered as a logic rationale to circumvent the mutations in 
PncA. But we found that the increased lipophilicity by increasing the length of the side 
chain was correlated to the increased toxicity of the compound, underlying the 
importance to consider the physiochemical properties of the new compound. Changing 
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the physiochemical properties will change the efficacy/toxicity profile of the resulting 
compound which can lead to rapid attrition from the discovery pathway. 
 
  Prokaryotic DNA-dependent RNA polymerase (RNAP) is an attractive target for 
developing new anti-TB agents. It is essential for the microbe survival and shows 
features that make it different from mammalian RNAP. 
 
  In this study, we used the RNAP assay to predict the inhibitory effect of different 
substances and combinations on the RNAP.  
 
  Myxopyronin, corallopyronin and ripostatin are attractive RNAP inhibitors for anti-
microbial drug researchers. Their mode of action is different than that of rifampicin 
(RIF) representing a possible solution for widespread RIF-resistance. 
 
 The results revealed MIC of myxopyronin and corallopyronin 6.25 and 12.5 µg/ml 
respectively, while ripostatin did not inhibit the bacterial growth up to concentration of 
25 µg/ml. 
 
 Corallopyronin showed low selectivity with selectivity index (SI) of 2. In addition, 
corallopyronin seems to be upon long storage transforms into highly toxic compound 
which affects the mammalian cell division through its toxic effect on the cellular 
microtubules leading to large multinucleated cells. 
 
 Myxopyronin showed higher safety margin with SI greater than 16.  It had no effect on 
the cell morphology as revealed from immunocytochemistry (ICC). 
 
 Myxopyronin showed synergistic effect with the commercially available 
antimycobacterial agent, ethambutol with FIC of 0.64. The all combinations between 
myxopyronin and ethambutol showed high antimycobacterial activity with wide safety 
margin with no detectable effect on the cellular structures with ICC staining even with 
concentrations much higher than their MIC.  
 
 Myxopyronin is highly bound to proteins. It has MIC against M. bovis BCG 6.25 
µg/ml in 100 % medium. In the presence of 50% FBS, it did not inhibit the bacterial 
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growth up to conc. 25 µg/ml. On the other hand, the antibacterial activity of the 
combination ethambutol with myxopyronin was not affected by adding the FBS. 
    
  LX079 was chosen by screening of a random library of compounds. It had SI > 10 
and it showed no morphological changes of the treated cell line at a concentration 25 
times higher than the MIC. 
 
 LX079 was tested for acute oral toxicity in mice. By calculating the cumulative 
percentage of death, the LD50 was estimated to be more than 250 mg/kg. 
 
  The pharmacokinetic (PK) profiles of LX079 in mice following IV (12.5 mg/kg) and 
oral (12.5 & 25 mg/kg) single dosing were evaluated. After IV administration, LX079 
exhibited short t1/2 of 0.43 h ± 0.27 with rapid clearance of 23.64 l. h-1. kg-1 ± 1.22. 
Theses findings were correlated with the in vitro results when the compound was 
incubated with mice pooled hepatic microsomal enzymes. LX079 had in vitro t1/2 of 
5.937 min ± 2.362 with hepatic intrinsic clearance of 221.81 ml . min-1/SMW ± 88.23 
when scaled from the in vitro t1/2. 
 
 The oral bioavailability of LX079 following single oral dosing at 12.5 and 25 mg/kg 
was 27.58 ± 2.46 and 32.66 ± 7.72 respectively and the whole concentration-time 
curves were below the level of the in vitro MIC. 
 
 LX079 needs to be recycled in the lead optimization process for achieving more 
stability. By using the molecular modification strategy, 20 analogues of LX079 were 
prepared and will be further tested for this task. 
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8. Appendix: 
Immunocytochemistry (ICC): 
Different combinations of myxopyronin and ethambutol at different concentrations 
were investigated in the ICC to confirm their safety and to predict if they could produce any 
changes in the cell morphology. Endoplasmic reticulum (ER) (Fig. 40), microtubules (Fig. 41) 
and actin stress fibres (Fig. 42) were stained after 18 hours incubation with the test 
compounds.  
  
  
  
 
Fig (40): Immunoflorescent staining of endoplasmic reticulum: A: Control, B: LX018, C: LX019, D: LX021, 
E: LX004, F: LX024. PtK2 cells were incubated with 20 µg/ml of different combinations for 18 hours. In 
comparison with control cells, treated cells show also normal appearance of the endoplasmic reticulum. 
D
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Fig. (42): Immunoflorescent staining of actin: A: Control, B: myxopyronin, C: ethambutol, D: LX018, E: 
LX019, F: LX021, G: LX004, H: LX024, I: LX079. PtK2 cells were incubated with 20 µg/ml of different 
combinations and 5 µg/ml in case of LX079 for 18 hours. In comparison with control cells, treated cells show 
also normal appearance of the actin stress fibres. 
Fig (41): Immunoflorescent staining of α tubulin: A: 
Control, B: LX018, C: LX019, D:LX021, E: LX004, F: 
LX024, G: LX079. PtK2 cells were incubated with 20 µg/ml 
of different combinations and 5 µg/ml in case of LX079 for 18 
hours. In comparison with control cells, treated cells show also 
normal appearance of the microtubules. 
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  In addition, (Fig. 41) shows the staining of microtubules after the treatment with 
LX079, the substance that was selected from the library of compounds to be further 
investigated. (Fig. 42) shows also the staining of actin stress fibres after the treatment with 
myxopyronin and ethambutol individually and the compound LX079. All treated cells show 
normal morphological appearance. 
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9. Abbreviations: 
 
ADME               Absorption, distribution, metabolism, and excretion  
APS                    Adenosine 5´ phosphosulfate 
ATP                   Adenosine triphosphate 
AUC                  Area under the curve  
BCG                  Bacille Calmette-Guérin  
BSA                   Bovine serum albumin  
CC                     Column chromatography  
CL                     Clearance  
Cmax                   peak concentration  
CYP                  Cytochrome P450 enzymes 
DCF                 2′,7′-dichlorofluorescein  
DCFH              2`,7`-dichlorodihydrofluorescein  
DCFH-DA       2`,7`-dichlorodihydrofluorescein diacetate  
DMSO             Dimethyl sulfoxide 
DNA                Desoxiribonucleic acid 
DOTS              Directly observed treatment short-course 
EBA                Early bactericidal activity  
ED                    Equilibrium dialysis  
EDTA              Ethylenediamine tetraacetic acid 
FASI                Fatty acid synthetase I  
FITC                Fluorescein isothiocyanate  
FPLC               Fast protein liquid chromatography  
h                       Hour 
His                    Histidine  
HIV                  Human immunodeficiency virus  
HMS                 Hepatic microsomal stability  
ICC                   Immunocytochemistry  
IMAC               Immobilized metal affinity chromatography  
INH                   Isoniazid  
kDa                   Kilodalton 
LB                    Luria Bertani medium 
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LogPow            Octanol–water partition coefficient 
Luc                   Luciferin 
min                   Minute 
mM                   Millimolar 
M                      Molar 
MDR-TB          multi-drug resistant TB  
M. TB               Mycobacterium tuberculosis  
MTT                 (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide 
NADPH            Nicotinamide adenine dinucleotide phosphate 
NTP                  Nucleotides (ATP, UTP, GTP& CTP) 
OADC              Oleic acid, albumin, dextrose, catalase 
OD                    Optical density 
OECD               Organisation for Economic Co-operation and Development  
PAGE               Polyacrylamide gel electrophoresis 
PBS                    Phosphate buffered saline  
PD                     pharmacodynamics  
PI                      Propidium Iodide  
PK                     Pharmacokinetics  
POA                  Pyrazinoic acid 
PPB                   Plasma protein binding  
PPi                     Pyrophosphate 
PTFE                 Polytetrafluoroethylene  
PS                      Phospholipid phosphatidylserine  
PZA                   Pyrazinamide  
QSAR                Quantitative structure activity relationship  
RED                  Rapid equilibrium dialysis device  
REMA             Resazurin microtiter assay  
RIF                   Rifampin  
RLU                Relative light unit 
RNA                Ribonucleic acid 
RNAP               DNA-dependent RNA polymerase  
RNAPI             RNA polymerase inhibitors  
ROS                 Reactive oxygen species   
rpm                 Rounds per minute 
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SDS                 Sodium dodecyl sulphate 
SMW               Standard mouse weight 
t1/2                                 Half-life  
TAE                Tris-Acetate-EDTA 
TB                    Tuberculosis 
TLC                 Thin layer chromatography  
U                       Unit 
UPR                 Unfolded protein response  
UV                    Ultraviolet light 
Vd                       Volume of distribution  
WHO                World Health Organization 
XDR-TB           Extensively drug-resistant TB  
 
 
